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Abstract

TARGETED THERAPIES FOR EWSR1-FLI1 TRANSLOCATED EWING FAMILY OF
TUMORS
By Daniel Andrew Russell Heisey, B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Christopher Newport University, 2011

Director: Anthony Faber, Ph.D.
Assistant Professor, Philips Institute, School of Dentistry

The EWSR1-FLI1 t(11;22)(q24;q12) translocation is the pathognomonic genomic
alteration in 85% of the Ewing Family of Tumors (EWFT) a malignancy of the bone and
the surrounding tissue, predominantly affecting children and adolescents. This
translocation results in the formation of a chimeric oncoprotein which acts as an aberrant
transcription factor that is currently not pharmaceutically druggable, driving the need for
more effective targeted therapies. The EWSR1-FLI1 translocation induces a variety of
changes including dysregulation of the epigenome and altered gene expression to drive
tumorigenesis, and consequently contributes to the hypersensitivity of EWFT to several

xiv
classes of chemotherapeutics. We sought to exploit these intrinsic sensitivities by
employing a matched pair of cell lines derived from the same patient with Ewing sarcoma
prior to and following chemotherapy, a panel of Ewing sarcoma cell lines, and several
patient-derived xenografts (PDX) collected at the time of relapse or autopsy, which led us
to the development of two novel combination targeted therapies for EWFT.
In our matched pair of EWFT cell lines, we found sensitivity to the Poly(ADPribose Polymerase (PARP) inhibitor olaparib was diminished following chemotherapy,
despite a predicted sensitivity. In addition, we discovered increased expression of the
antiapoptotic protein BCL-2 in the chemotherapy-resistant cells, conferring apoptotic
resistance to olaparib. We found that EWS-FLI1 increases BCL-2 expression; however,
inhibition of BCL-2 alone is insufficient to sensitize EWFT cells to olaparib, revealing a
dual necessity for BCL-2 and BCL-XL (BCL2L1) in EWFT survival. These data reveal
BCL-2 and BCL-XL act together to drive olaparib mediated apoptotic resistance in Ewing
sarcoma and identify a novel, rational combination therapy using olaparib and the BCL2/BCL-XL inhibitor navitoclax.
In addition, using high throughput drug screening we have identified a novel
epigenetic susceptibility in EWFT to GSK-J4 (GlaxoSmithKline), an inhibitor of lysine 27
of histone 3 (H3K27) demethylases: ubiquitously transcribed tetratricopeptide repeat, X
chromosome (UTX) and Jumonji D3 (JMJD3). Treatment with GSK-J4 leads to a
decrease in H3K27 acetylation (H3K27ac) and ultimately, the silencing of EWS-FLI1 gene
targets.

xv
We sought to sensitize GSK-J4-mediated inhibition of EWS-FLI1 targets by
blocking RNA polymerase II activity using the Cyclin Dependent Kinase 7 (CDK7)
inhibitor THZ1. By targeting CDK7-mediated transcription we were able to sensitize
EWFTs to H3K27 demethylase inhibition. We therefore propose co-targeting of H3K27
demethylases and CDK7 acts as a surrogate EWS-FLI1 inhibitor. Given the difficulties
targeting EWS-FLI1, these strategies may present viable clinical therapies.
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CHAPTER 1 - Introduction

Targeted Cancer Therapies
For many decades, systemic chemotherapy has been the cornerstone of cancer
treatment despite toxicity, low therapeutic indexes, and challenges in drug discovery (1-3).
Recent advances in molecular profiling and genomics have led to a greater understanding
of cancer biology (4-6), allowing for the optimization of treatment using targeted therapies
(7-9). This technological revolution has led to the emergence of new studies aimed at the
systemic mapping of cancer genomics and the characterization of pharmacological
vulnerabilities (10, 11). These include programs such as the Cancer Genome Atlas
(TCGA) , the Cancer Cell Line Encyclopedia (CCLE), and the Genomics of Drug
Sensitivity in Cancer (GDSC) (12, 13), which have helped to identify many of the genes
responsible for disrupting the cellular processes which lead to cancer. Despite the
complexities found in cancers, they are often driven by specific genetic aberrations known
as oncogenes, whose direct inhibition can have a dramatic effect on cancer growth and
survival (14, 15). This “oncogene addiction” serves as the rationale behind the
development of targeted therapies, aimed at the pharmaceutical impairment of cancer
specific oncogenes. Targeted therapies are effective due to their low toxicity and highly
specific anti-tumor activity in a cytotoxic or cytostatic manner. This is accomplished by
designing drugs that target oncogenes specific to each cancer type, which by definition are
more heavily relied on by cancer cells for survival compared to normal healthy cells (1).
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One of the first and most significant of these targeted therapies is imatinib mesylate
(Novartis) (16). Imatinib is a small molecule kinase inhibitor with specificity for BCRABL, the fusion protein resulting from a chromosomal translocation which drives
oncogenesis in chronic myeloid leukemia (CML) (17). Imatinib has been employed to
successfully treat CML while having little effect on normal cells, demonstrating its
specificity and effectiveness as a targeted therapy (18). Unfortunately, a common
occurrence in cancer is acquired resistance which becomes problematic for single agent
targeted therapies, driving the need to develop and implement new generations of
inhibitors with higher efficacy and the employment of combination targeted therapies (3,
7).

The Ewing Family of Tumors
The Ewing Family of Tumors (EWFT) are the second most common form of
pediatric bone cancer, with ~250 new cases diagnosed in the United States each year (19)
and accounts for roughly one-third of all pediatric bone tumors (20). The malignancy was
first described in 1921 by its namesake James Ewing, where it was distinguished as a
separate disease from osteosarcoma and identified as being highly sensitive to radiation
therapy (21). The Ewing Family of Tumors consists of Ewing Sarcoma of the bone (ES),
Extraosseous Ewing Tumors (22), and Peripheral Primitive Neuroectodermal Tumors
(PNET), all of which share a common family of translocations. These translocations
consist of the amino terminus of one the FUS/TLS, EWSRI and TAF15 (FET) family of
RNA-binding proteins fused to the carboxy terminus of one of the E26 transformation-
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specific (ETS) family of transcription factors. This fusion results in the formation of
proto-oncogenes which display neomorphic functions which deregulate the transcriptome
and epigenome of cells and have been identified as the driving force behind EWFT
tumorigenesis. (23). This is accomplished through FET/ETS oncoproteins binding to ETS
gene targets at GGAA binding motifs located within enhancer or promoter regions, which
results in chromatin remodeling that alters gene expression (24-26) and to a lesser known
extent results in the downregulation of tumor suppressors (27, 28).
Occurrence rates are higher in the male population compared to female (sex ratio of
1.5:1) and is predominantly higher among Caucasians, with a much lower incidence in
people of Asian and African descent. Of note, there is a difference in the size and
grouping of the GGAA ETS binding motifs found between Caucasian and African/Asian
populations which may help explain the observed differences in disease frequency.
However, within all population’s a high number of GGAA microsatellites occur at ETS
target genes, with 20-26 repeats found in European samples and 30 or more in African
samples. These greater numbers of GGAA consecutive repeats may be attributed to a
more aggressive phenotype and help explain the lower survival rates found in African
populations despite their decreased rate of occurrence. Despite these findings, a possible
genetic distinction between the 10 fold greater rate of occurrence in people of European
ancestry still remains unclear (24, 25, 29, 30).
Recent advances have been made in the treatment of primary EWFT tumors using
systemic chemotherapy to increase the 5-year survival rate to 70%. Unfortunately, 25% of
patients are asymptomatic for micrometastasis at the time of diagnosis and these patients,
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or those who relapse following chemotherapy have a 5-year survival rate of less than 30%
(19, 31). The current standard of care (VDC-IE: Vincristine, Doxorubicin,
Cyclophosphomide – Ifosfamide and Etoposide) for EWFT in North America relies
heavily on adjuvant and neoadjuvant systemic chemotherapy followed by surgical
resection of the primary tumor and continued chemotherapy or radiation therapy (32-34).
In a study by the Children’s Oncology Group (COG), the event free survival (EFS) was
significantly increased in patients treated with a more intense regimen of VDC-IE
chemotherapy at 2-week intervals compared to patients treated at 3-week intervals (COGAEWS0031 [NCT00006734]), which suggests more aggressive treatment regimens are
necessary for improved patient outcomes. Due to the aggressive nature of the disease, a
high prevalence of metastasis/relapse and the intense chemotherapy treatments required,
there exists a dire need to develop more potent and effective targeted therapies.

5

FET/ETS Fusion

Chromosomal Translocation Frequency

EWSR1-FLI1

t(11;22)(q24;q12)

~85%

EWSR1-ERG

t(21;22)(q22;q12)

~10%

EWSR1-ETV1

t(7;22)(p22;q12)

<1%

EWSR1-ETV4

t(17;22)(q12;q12)

<1%

EWSR1-FEV

t(2;22)(q35;q12)

<1%

FUS-FEV

t(2;16)(q35;p11)

<1%

FUS-ERG

t(16;21)(p11;q24)

<1%

Table 1.1 Fusions which result in EWFT.

EWS
EWS is a nuclear protein encoded by EWS RNA binding protein 1 (EWSR1) and is
a member of the FET family of RNA binding proteins. Within this family are Fused in
Sarcoma (FUS), EWSR1, TATA-Box binding protein Associated Factor 15 (TAF15), and
translocations of these FET family of genes has been associated with a number of diseases
(31, 35, 36). The carboxy-terminus of EWS consists of its RNA binding domain and is
responsible for its ability to interact with RNA splicing factors while the amino-terminus
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of EWS contains a transcription activation domain which is maintained in translocations
that result in EWFT. EWS is considered an intrinsically disordered protein (IDP) due to its
repetitive (SYGQQS) low complexity amino acid sequence Prion-like domain, located
within the transcriptional activation region of the N-terminus, and is hypothesized to allow
for its transcriptional activation through the process of multimerization (37, 38). This
subsequent multimerization allows for the aggregation of EWSR1 and imbues phase
transition properties which are essential for the stabilization required to recruit coactivators and the chromatin remodeling complex BRG1/BRM-associated factor (BAF) to
induce the gene activation profiles associated with EWFT when translocated (39-41).

ETS
The ETS (E26 Transformation-Specific) family of transcription factors was first
discovered and initially named while researching the avian erythroblastosis virus, E26 in
1983 (42). This group contains 28 transcription factors in humans that all share a highly
conserved DNA binding domain (ETS domain), consisting of a winged helix-turn-helix
which binds the major groove, making it critical for a vast majority of cellular processes as
they occupy 15% of all human promoters and regulate pathways responsible for cell cycle
regulation, differentiation, proliferation, and apoptosis (30, 43-45). In addition, knocking
out the ETS family member: Friend Leukemia Integration 1 transcription factor (FLI1) has
proven to be embryonic lethal demonstrating its importance in development (46, 47). For
these reasons the ETS family members are often implicated in the tumorigenesis of
multiple cancer types (43-45, 48, 49). This often occurs through their direct amplification
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or as a result of gene fusions such as TMPRSS2/NDRG1-ERG (transmembrane protease
serin2/N-Myc downstream regulated 1 - ETS-related gene) in prostate cancer (50) and
EWSR1-ETS in Ewing Sarcoma. In addition to the DNA binding domain, many ETS
family members possess an additional pointed (PNT) domain, which plays a role in
protein-protein interaction, however the PNT domain in FLI1 is lost in the EWS-FLI1
translocation (43, 48, 49, 51).
The EWSR1-FLI1 translocation is present in 85% of all EWFT cases, while the
remaining 15% harbor EWSR1-ERG t(21;22)(p22;q12), EWSR1-ETV1 t(7;22)(p22;q12),
EWSR1-ETV4 t(17;22)(q12;q12), or EWSR1-FEV t(2;22)(q33;q12) translocations (44, 52,
53). Both FLI1 and ERG expression is relatively low in adult tissues, however they are
highly expressed in both the spleen and bone marrow due to their role in hematopoiesis
(47, 54). In addition, the FLI1 and ERG transcription factors involved in EWFT have been
shown to induce very similar clinical phenotypes and gene expression changes, likely due
to only minor differences in their N terminus, suggesting they share gene targets and serve
similar functions that contribute to disease when translocated to EWSR1 (27, 55).

EWS-FLI1
Within the Ewing Family of Tumors the majority are driven by the specific
EWSR1-FLI1 t(11;22)(q24;q12) translocation event, which results in the DNA binding
domain of FLI1 fused to and regulated by the strong transcriptional activation domain of
EWSR1 (27, 56-60). FLI1 was first identified over 20 years ago, where it was quickly
found to represent the dominant translocation event which causes Ewing Sarcoma (Fig.
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1.1). The resulting EWS-FLI1 fusion retains a more potent level of transcriptional activity
compared to the wild type FLI1 which has a relatively weak transcriptional activation
domain (61). The remaining 15% of EWFTs harbor alternative EWS-ETS fusions whose
functions mimic that of EWS-FLI1 (45, 49). Both EWSR1 and FLI1 are required for
transformation, as deleting portions of either gene results in a loss of the transformation
phenotype (25).
In addition to the gene specific chimeric fusion, there are subtypes of each
translocation determined by the breakpoint regions of EWSR1 and FLI1. The most
common EWS-FLI1 transcript variant is that of EWSR1 exon 7 fused to FLI1 exon 6 (7/6
fusion), and is known as type 1 (62). These specific EWS-FLI1 oncoprotein subtypes were
previously reported to influence factors such as the tumorigenicity and propensity to form
metastasis (63, 64). However, more current studies have refuted this claim, suggesting that
the fusion subtype has no effect on clinical phenotypes (52, 65). Recent studies have
shown that the EWS-FLI1 translocation is not only required for EWFT tumorigenesis, but
its expression is able to transform mesenchymal stem cells (MSCs), the proposed cell of
origin of EWFT. When the EWS-FLI1 translocation is expressed in pediatric MSCs, a
gene expression profile is induced which emulates that of EWFT (26, 66, 67).
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Figure 1.1 EWS-FLI1
Chromosomal translocation which creates the EWS-FLI1 oncoprotein, binding the TAD of
EWS to the ETS domain of FLI1.

Cell of Origin
Within the EWFT there is a lack of knowledge concerning the most likely cell
lineage of origin, whose identification would serve to elucidate more reliable markers of
disease and therapeutic agents. Early studies have demonstrated that a subset of EWFT
display neural markers, and expression of the EWS-FLI1 translocation in neuroblastoma
cells is sufficient to induce a gene expression profile associated with EWFT. The
expression of EWS-FLI1 in pediatric mesenchymal stem cells induces the expression of
genes responsible for neuroectodermal differentiation (57, 68). However, more recent
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data suggests EWFT is of mesenchymal origin, and that it may exude a partial neural
phenotype as a consequence of the EWS-FLI1 reprogramming.
Riggi and colleagues (69) demonstrated that expression of the EWS-FLI1
translocation in bone-derived human mesenchymal stem cells (hMSC) alone is enough to
transform the cells and generate tumors which mimic that of the Ewing Family of Tumors.
This translocation induces a cellular phenotype analogous to the small round blue cells that
are the hallmark of EWFT, and a gene expression profile comparable to FLI1 target gene
expression. In addition, the knockdown of EWS-FLI1 in EWFT cell lines results in the
cellular expression of cell surface markers and gene expression profiles closely resembling
mesenchymal stem cells (26, 66, 67, 70, 71). Of the various progenitor cell types that have
been proposed, only mesenchymal stem cells are able to stably express the EWS-FLI1
fusion. In addition, the CD99 antigen, which is normally expressed on the surface of
hMSC is the most widely used histological marker for EWFT detection (72). Taken
together, this data would strongly suggest that these tumors arise from a mesenchymal
stem cell of origin.

EWFT Transcriptional Regulation
EWS-FLI1 preferentially binds to specific microsatellite motifs consisting of
repetitive GGAA sequences. Interestingly, the GGAA core consensus sequence is a direct
binding target of wild type FLI1, and only the translocated EWS-FLI1 results in the
activation of de novo enhancer elements. Gene activation is achieved when GGAA motifs
contain 4 or more repeats, and optimal binding is attained at 12-14 repeats (25, 30). EWS-
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FLI1 has a higher binding affinity to these repeats than wild type FLI1 resulting in FLI1
displacement and consequential alterations of gene expression (24, 39, 73). More
importantly, the presence of multiple GGAA microsatellite repeats has been detected in
75% of the genes activated by EWS-FLI1, while 85% of genes repressed by this chimeric
protein displayed non-repetitive GGAA sequences (26). In addition, the clinical
phenotypes of other EWS-ETS fusions such as EWS-ERG mimic that of EWS-FLI1
suggesting a similar global deregulation of gene expression within EWFT (55).
Although the exact functions of EWS is not currently understood, the EWS aminoterminus is shown to exhibit direct interactions with transcriptional machinery such as
RNA polymerase II and the co-activator p300/CBP (26, 39, 58, 74, 75). Both wild type
EWSR1 and the EWS-FLI1 fusion are able to interact with the BRG1/BRM-associated
factor (BAF) chromatin remodeling complex which contributes to gene activation. This
leads to the recruitment of the BAF complex to tumor-specific enhancers at FLI1 binding
targets, resulting in their activation (39). However, the method of EWS-FLI1 gene
repression is poorly understood. It is hypothesized to be an indirect mechanism, through
miRNA and epigenetic mechanisms which alter post-transcriptional gene regulation, as
EWS-FLI1 does not bind directly to the enhancers of repressed genes (76, 77). Another
possibility is through the Enhancer of Zeste homolog 2 (EZH2), a bona fide EWS-FLI1
gene target, which is directly upregulated by EWS-FLI1, and is the enzymatic subunit of
the polycomb repressive complex 2 (PRC2) responsible for methylation of histone 3
Lysine 27 (78-81). Increases in methylation at lysine 27 are marks of repressed
chromatin, and the upregulation of EZH2 suggests a method of EWS-FLI1 mediated
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indirect gene silencing through the remodeling of chromatin. It has also been
demonstrated that wild-type FLI1 binds to single GGAA repeat motifs and once bound is
capable of recruiting the p300 co-activator. However, the EWS-FLI1 oncoprotein has a
higher binding affinity for these GGAA motifs but requires multimerization for p300 and
BAF recruitment, effectively silencing many EWS target genes with less than 4 GGAA
motifs (26).

Research Goals
The Ewing Family of Tumors serves as an excellent model to study the paradigm
that chromosomal translocation-driven cancers represent. Due to the low mutational
burden found in EWFT and the specific FET-ETS driver events, we are presented with a
unique transcription factor driven deviation from normal cell regulatory processes (82).
Unlike many specific oncogene addictions which we are able to pharmaceutically inhibit,
EWS-FLI1 is not a viable target, however the changes in gene expression that it causes
represent potential therapeutic targets (20, 58). The principle goal of our research is to
investigate and address a means of pharmaceutically targeting the driving force behind
EWFT pathogenesis: the EWS-FLI1 translocation, through indirect targeting of its
downstream effects. Taken together, these studies hope to expand upon the mechanisms by
which the EWS-FLI1 translocation evades traditional therapies, and to develop novel
targeted therapies which can be utilized in a clinical setting.
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The work herein evaluates and achieves the following aims:
1.

Elucidate the mechanism by which EWFT become resistant to Poly(ADPribose) polymerase inhibition (PARPi) and develop a means of countering
this resistance. EWFT are extremely sensitive to PARPi in vitro due to their
lack of efficient homologous recombination repair. However, the PARP1/2
inhibitor olaparib had little efficacy in a clinical trial comprised of patients with
chemo-refractory disease (83). Understanding the disconnect between the
observed deficiency of PARP inhibitor activity, and the altered gene expression
profile induced by EWS-FLI1 (which likely contributes to chemotherapy
resistance), is critical to better understand and develop new targeted therapies
effective in patients who relapse or acquire drug resistance.

2. Identify a means of pharmaceutically targeting the vast genomic
remodeling that occurs as a result of EWS-FLI1. This work focuses on
targeting the epigenetic mechanisms that EWS-FLI1 utilizes to dysregulate the
epigenome. This refers to DNA modifications which can result in the alteration
of gene expression without changing the sequence of DNA. These
modifications are caused by the methylation of DNA at cytosine residues, the
remodeling of chromatin, and through modifications to histone tails which
result in their methylation or acetylation (84, 85). EWS-FLI1 is capable of
altering the expression of histone marks at enhancer and super-enhancer
regions, these resulting changes to the epigenome alter the transcriptional
activity of genes. Two of the histone modifications most highly regulated by
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EWS-FLI1 are H3K27ac and H3K4me1, both ubiquitous markers of active
enhancers, and are found to be enriched at known EWS-FLI1 gene targets (26,
76). By combining histone demethylase and RNAP II inhibitors we sought to
disrupt the EWS-FLI1 transcriptional machinery and H3K27ac modifications
which promote EWFT oncogenesis.

1

CHAPTER 2 – Materials and Methods

Cell Lines
A673 (ATCC® CRL-1598™) and HEK293T cells were cultured in DMEM
(Gibco) with 10% FBS (Seradigm) and 1µg/ml penicillin and streptomycin. CHLA9 and
CHLA10 cells were grown in DMEM with 20% FBS, 1ug/ml penicillin and streptomycin,
and 1% Insulin-Transferrin-Selenium 100x (Gibco). SK-ES-1(ATCC® HTB-86™) was
grown in DMEM/F12 (Corning) with 15% FBS and 1ug/ml of penicillin -and
streptomycin. ES4 and EW16 cells were grown in RPMI1640 (Lonza Group) with 10%
FBS and 1µg/ml of penicillin and streptomycin. Routine mycoplasma testing was
performed on all cell lines. CHLA9, CHLA10 and the PDX models TX-E-270x and TX-E351x were obtained from the Children’s Oncology Group (COG) Cell Culture and
Xenograft Repository, special thanks to Dr. C. Pat Reynolds, Texas Tech University
Health Sciences center. PDX models SA10233 and SA13542 were obtained from Crown
Bioscience. Ex vivo PDX lines were derived using selective trypsinization (86) over
consecutive passages and cultured in RPMI 1640 with 10% FBS. ES4, EW16, HEK293T,
A673 (ATCC® CRL-1598™), and SK-ES-1 (ATCC® HTB-86™), were obtained from
either the Molecular Center Therapeutics laboratory at Massachusetts General Hospital
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which performs routine testing of cell lines using STR and SNP analysis, or from the
American Type Culture Collection (ATCC).

Antibodies and Reagents
Primary antibodies used for Western blotting were GAPDH (Santa Cruz sc-3233) ,
RNAP II (Santa Cruz sc-56767), FLI1 (Santa Cruz sc-365294) Santa Cruz Biotechnology
(Dallas, TX); Cleaved PARP1 (Cell Signaling 5625), BCL-2 (Cell Signaling 4223), BCLXL (Cell Signaling 2764), MCL-1 (Cell signaling 5453), p-Ser2 RNAPII (Cell Signaling
13499), p-Ser5 RNAPII (Cell Signaling 13523), CCND1 (Cell Signaling 2922), EZH2
(Cell Signaling 5246), Tri-Methyl-Histone H3 (Lys27) (Cell Signaling 9733), Histone H3
(Cell Signaling 3638), PARP1 (Cell Signaling 9532), pH2A.X (Cell Signaling 9781), and
BIM (Cell Signaling 2933) from Cell Signaling Technology (Beverly, MA); FLI1 (Abcam
ab15289), NPY1R (Abcam ab91262), from Abcam (Cambridge, UK); Acetyl-Histone H3
(Lys27) (Active Motif 39133), from Active Motif (Carlsbad, CA). Secondary antibodies
used were mouse IgG (GE Healthcare Life Sciences NXA931) and rabbit IgG (GE
Healthcare Life Sciences NA934) GE Healthcare (Little Chalfont, United Kingdom). IgG
(Santa Cruz sc-2027) for immunoprecipitation was from Santa Cruz Biotechnology
(Dallas, TX). Olaparib (AZD-2281) was from Abmole (Houston, TX), A-1331852,
navitoclax (ABT-263) and venetoclax (ABT-199) were kindly provided by AbbVie Inc.
(North Chicago, IL), GSK-J4 and THZ1 were from Abmole (Houston, TX).

Western Blotting

17
Cell lines and tumor lysates were prepared using standard procedures (87) and lysis
buffer (50mM Tris, 15mM NaCl, 1%NP-40, 1% SDS, 0.5% NaDOC, 1mM EDTA, 1mM
EGTA, 10% glycerol, protease and phosphatase inhibitors), incubated on ice for 15
minutes and centrifuged at 10,000 rpm for 10 minutes. Tumor lysates were homogenized
using the Tissuemiser (Fisher Scientific) in RIPA lysis buffer (15mM NaCl, 50mM Tris,
1%NP-40, 1%SDS, 0.5% NaDOC, glycerol, protease and phosphatase inhibitors), followed
by a 30 minute incubation on ice and 10 cycles of sonication - 30 seconds on 30 seconds
off (Bioruptor 300, Diagenode). Equal concentrations of lysates were run using the
NuPAGE Novex Midi Gel system using 4-12% Bis-Tris Gels (Invitrogen), and transferred
onto PVDF membranes (PerkinElmer). Membranes were blocked in 5% non-fat milk in
TBST, primary antibodies were incubated overnight. Chemiluminescence was detected
after incubation with SuperSignal West Femto (Thermo Fisher) using a Syngene G:Box
camera (Synoptics).

Immunoprecipitation
Immunoprecipitation experiments were performed as previously described (87).
A673 cells were lysed using the same buffer for western blotting experiments. 25 µl of
protein A sepharose beads (GE Healthcare, Bio-Sciences) were added to the lysates
followed by 0.5 µg of the indicated antibodies: BCL-2 (Cell Signaling 4223), H3K27ac
(Diagenode C15410196), or rabbit IgG (Santa Cruz sc-2027). Samples were incubated
with motion at 4°C overnight. Immunoprecipitated complexes were washed three times in
the same lysis buffer and for IP’s were run using 4-12% Bis-Tris Gels (Invitrogen), and
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transferred onto PVDF membranes (PerkinElmer) in parallel with whole cell lysates
containing 5% of the immunoprecipitation input. Membranes were blocked in 5% non-fat
milk in TBST, primary antibodies were incubated overnight. Chemiluminescence was
detected after incubation with SuperSignal West Femto (Thermo Fisher) using a Syngene
G:Box camera (Synoptics). For ChIP, immunoprecipitated complexes were fixed using
1% formaldehyde and isolated, DNA was purified and Quantitative RT-qPCR of primers
for the 5’ region of the FLI1 binding site of putative enhancers was run on the 7500 Fast
Real-Time PCR System (Applied Biosystems) measuring fluorescence of SYBR Green
(Applied Biosystems). Primers used are listed in table 2.1 as described within each chapter.
Results were normalized to the input chromatin using the Delta-Delta Cycle Threshold
method.

Immunohistochemistry
BCL2 IHC was performed on a DAKO Omnis autostainer using Clone 124
(DAKO; predilute 10 minutes), with high pH antigen retrieval with standard HRP/DAB
detection, using tonsil control. BCL- XL IHC was performed using a Leica Bond
autostainer using clone H-5 (Santa Cruz Biotech; 1:250), per manufacturer instructions and
standard HRP/DAB detection, using manufacturer recommended control. Expression of
BCL-2 and BCL- XL: Cytoplasmic immunostaining in non-necrotic/preserved areas of
whole sections was evaluated by surgical pathologist (SCS) in accordance with IRB
HM20002579 and scored semi-quantitatively as 0 (negative); 1+ (weak positive); 2+
(moderate positive); or 3+ (strong positive). Proportion positive was scored as focal
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(<10%); multifocal (10-50%), or diffuse (>50%). Images were taken using an Olympus
DP73 using Olympus cellSens imaging, version 1.16.

Immunofluorescence
Cells were grown in 6-well plates on cover slips. Cells were treated for 24 hours
with the indicated drug treatment. Following completion cells were fixed in cold methanol
followed by a 10 minute incubation in 0.2% Triton X-100. Cells were then blocked in 5%
normal goat serum with 0.1% tween in PBS for 1 hour at room temperature. Cells were
incubated with pH2A.X (Cell Signaling 9718S) diluted with antibody buffer (1% BSA in
0.1% tween in PBS) and incubated in a humid chamber at 4°C overnight. Following
incubation, Alexa Fluor 488 labeled antibody was added for 1 hour at room temperature.
Cells were washed, and the nucleus was stained with DAPI. Slides were mounted and
sealed with vectashield and imaged on under a zeiss axio observer 7 fluorescent
microscope. Quantification of pH2A.X was performed using matching capture parameters
in randomly selected regions of interest. Using ImageJ, images were converted to
grayscale binary and individual cells were counted and analyzed based on pH2A.X
fluorescent intensity as RFU (88).

Apoptosis
Cells were prepared using standard procedures described previously (89) and were
seeded in triplicate. Cells were treated for 24 , 48, or 72 hours with the indicated drug
treatment. Following treatment cells were stained with propidium iodide and Cy5-Annexin
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V and analyzed using the Guava easyCyte FACS machine (Millipore). Cells were
considered apoptotic if they stained positive for Annexin V alone or Annexin V and
propidium iodide.

Cell Cycle Analysis
Cells were seeded in triplicate in 35mm dishes and treated as indicated. After 24
hours cells were trypsinized and re-suspended in binding buffer with 0.1% Triton in PBS
and stained with Propidium Iodide, followed by incubation for 20 minutes at 37 °C and
analyzed using the Guava easyCyte FACS Machine.

Cell Viability Assays
For CellTiter-Glo assays, dose response curves, and IC50 curves, cells were seeded
at 3,000 cells per well in 96-well flat bottom black plates and treated the next day in
quadruplicate with serial dilutions of the indicated drugs. After 72 hours, 25µl of CellTiterGlo (Promega) was added to each well and read on a Synergy H1 Hybrid Reader (BioTek).
For crystal violet staining, cells were seeded at a density of 50,000 cells per well in 35mm
dishes. The next day cells were treated with the indicated drugs and allowed to grow for 35 days until the control (no rx) well grew to confluency. The cells were then fixed with
glutaraldehyde (Sigma-Aldrich) and stained with 0.1% crystal violet (Sigma- Aldrich).

Cleaved Caspase-3 Activity Assays
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Cells were seeded in quadruplicate at 5 x104 in a 96 well plate. After 24 hours, the
medium was changed, and cells were treated for 24 hours with the indicated drug
treatment. Cells were assayed for caspase-3 activity as per the manufacturer’s protocol
(Cell Signaling Technology, 5723S). Plates were read after a 2 hour incubation period.

RNA Isolation and RT-qPCR
Total RNA was isolated from cells grown at sub-confluency using the Quick-RNA
MiniPrep Kit (Zymo Research) for olaparib/navitoclax treatments or the Isolate II RNA
Mini Kit (Bioline) for GSK-J4/TZH1 treatments, and RNA was reverse-transcribed to
cDNA using the iScript Adv cDNA Kit for RT-qPCR (BIO-RAD) on a GeneAmp PCR
System 9700 (Applied Biosystems). Quantitative RT-PCR of reported primer sets and βactin was run on the 7500 Fast Real-Time PCR System (Applied Biosystems) measuring
fluorescence of SYBR Green (Applied Biosystems). Primers used as described in each
chapter are listed in table 2.1. Results were normalized to ACTB using the Delta-Delta
Cycle Threshold method. The melting curves of the primers are included in Figure 3.7.
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Gene

Forward Primer
BCL2
CTGCACCTGACGCCCTTCACC
EZH2
GTTCAAAACTCGGGGGTGGT
ACTB
AGAGCTACGAGCTGCCTGAC
NPY1R
CCATCGGACTCTCATAGGTTGTC
STEAP1
GGCAATACTGGCTCTGTTGGCT
PKRCB1
AAAGAGATCCAGCCCCCTTA
LOX
GCGACGACCCTTACAACC
CCND1
TCGAGAGGCCAAAGGCTGGT
NPY1R
CCATCGGACTCTCATAGGTTGTC
NPY1R (ChIP, putative enhancer) TCATCCTTGGGCTTCTGTACC
EZH2
AACCCGCAAGGGTAACAAA
EZH2 (ChIP, putative enhancer)
CAGCTTTGCGGAAAAACTCCA
NKX2.2
CAGCGACAACCCGTACAC
NKX2.2 (ChIP, putative enhancer) GGCCCCTTGAGACAGGTTGA

Reverse Primer
CACATGACCCCACCGAACTCAA
CACCACTAGGAGCGGCCAG
AGCACTGTGTTGGCGTACAG
GACCTGTACTTATTGTCTCTCATC
GCGTGTATTGTGCCCAGTAGAAG
TATCAGTGGGGGTCAGTTCC
GGACGCCTGGATGTAGTAGG
GGGGTTTTACCAGTTTTATTTCTAGAC
GACCTGTACTTATTGTCTCTCATC
AAGGACCCAGCTGCTTTTCAG
TGATCACCGTTAACCATCATAACT
TGTGGTGGATGAACATCACTCTT
GACTTGGAGCTTGAGTCCTGA
CCTGAGGCCAAGTTTCCATCC

Table 2.1 List of Primers

Gene Expression and Knockdown Studies
The EWS-FLI1 Type1 fusion plasmid (plenti4-FLI1) and Empty Vector (plenti4EV) was a gift from Miguel Rivera (26). To knockdown BIM, siRNA transfection was
performed with Lipofectamine 2000 Transfection reagent (ThermoFisher, 11668-019) and
Bim siRNA Hs_BCL2L11_5 FlexiTube siRNA (Qiagen, SI02655359). The siRNA ONTARGETplus Non- targeting Pool (Dharmacon, D-001810-10-05) was used as a control
and cells were treated 24 hours after transfection. To over express GFP, BCL-2 and BCLXL CHLA10 cells were transfected using Lipofectamine 2000 Transfection reagent
(ThermoFisher, 11668-019) and GFP in a pCDNA3.1 vector (GenScript), BCL-2 in a
pcDNA3.1, BCL-XL in a pcDNA3.1 vector. 24 hours after transfection lysates were
collected to confirm expression and cells were treated with olaparib for 24 hours before
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measuring viability using CellTiter Glo. For EWS-FLI1 knockdown experiments, short
hairpin RNA (shRNA) in a pLKO.1 vector was used (26) in parallel with a shRNA control
scramble sequence (MISSION pLKO.1-shRNA control plasmid DNA), both shRNA have
pLKO.1 puromycin-resistant backbones. shRNA transduction methodology has been
previously described (87). For siRNA knockdown studies with TP53, siGENOME
SMARTpool Human TP53 (ThermoFisher, M-003329-03) and siGENOME Control Pool
Non-Targeting #2 (Dharmacon, D-001206-14-05) were used together with Lipofectamine
2000 and cells were treated with olaparib 24 hours after transfection.

Animal Experiments
For xenograft models, 5x106 cells were injected subcutaneously into the flank of 68-week-old Nod/SCID gamma (NSG) mice. The Patient Derived Xenograft Models
SA10233 and SA13542 were obtained from Crown Bioscience, TXE-270x and TXE-351x
were obtained from the Childhood Cancer Repository (TXCCR.org), and 5x105 cells were
injected into the flank of NSG mice subcutaneously. Treatment began when tumors
reached ~100-200mm3 and mice were randomized into treatment cohorts. Tumor size and
mouse weight was measured 3 days per week with a digital scale and calipers, where tumor
volume was calculated as length x width2 x 0.52. Navitoclax and olaparib were
administered by oral gavage. Navitoclax was dissolved in 60% Phosal 50 PG, 30%
PEG400, and 10% Ethanol, for a final dosage of 80mg/kg of body weight. Olaparib was
dissolved in 10% hydroxypropyl-β-cyclodextrin for a final dosage of 100mg/kg of body
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weight. GSK-J4 and THZ1 were administered by intraperitoneal injection (IP). GSK-J4
was dissolved into DMSO for a final dosage of 50mg/kg of body weight. THZ1 was
dissolved 10% DMSO and D5W for a final dosage of 10mg/kg of body weight. All drugs
were administered once per day 5 days/week. For pharmacodynamics studies, tumor
bearing mice were treated with drug for 3 days, and tumors were harvested on the 3rd day
2 hours after the final treatment. Tumors were flash frozen in liquid nitrogen. For the
blood toxicity study, NSG mice were treated with no drug (No Rx), navitoclax, olaparib, or
the combination. At 3 and 7 days mice were exsanguinated, and blood was sent to
IdexxBioResearch for testing. The recovery cohort was treated for 7 days and allowed 24
hours of recovery from treatment before exsanguination. All animal experiments were
approved by the Virginia Commonwealth University Institutional Animal Care and Use
Committee (IACUC protocol#AD10001048).

Dataset Analysis
The online database for publically accessible drug sensitivity data
(www.cancerRxgene.org) was used to generate Figure 3.3C. The CCLE (90) was used to
analyze expression between FLI1 and BCL-2 Figure 3.13D. The data analyzed for MCL-1
expression among sarcomas (Fig. 3.3D) was obtained from the R2 genomics analysis and
visualization platform, r2.amc.nl/.

Statistical Considerations
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For gene expression analyses and the complete blood count analysis (CBC),
significance was determined using the non-parametric Mann-Whitney U test. Differences
were considered statistically significant if P < 0.05. All other analyses were performed
using the Student’s t Test and considered statistically different if P<0.05. Asterisks
indicate levels of significance ns(P ≥ 0.05), *(P < 0.05), **(P < 0.01), ***(P < 0.001),
****(P < 0.0001).

Synergy Assays
Cells were seeded at 3 × 103 cells in a 96-well plate. 24 hours after seeding, cells
were treated with varied concentrations of navitoclax (0 to 2 M) and olaparib (0.1 to 10
M) for 72 hours, or cells were treated with varied concentrations of GSK-J4 (0 to 2.5 M)
and THZ1 (0.01 to 160 M) for 48 hours followed, by measurement of cell viability by
CellTiter-Glo. Percent viability was constrained to a maximum of 100. Percent over the
bliss score was calculated as previously described (91).
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Chapter 3 - The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape
PARP Inhibitor Toxicity
Introduction
The driving force behind oncogenesis in EWFT is the EWS-FLI1 translocation,
which is currently undruggable, and effective targeted therapies for treatment remain
elusive. Recent findings have highlighted the role EWS-FLI1 plays to induce a wide range
of changes throughout the epigenome, affecting both histone marks and enhancers (26, 36,
73, 92, 93), leading to the simultaneous enhanced expression of tumor oncogenes and the
reduced expression of tumor suppressors (26). However, these studies have yet to reveal
specific, druggable targets with associated clinically available therapies. Due to the lack of
any single druggable gene target responsible for EWFT oncogenesis, we have explored
two different strategies to treat the disease.
The first approach is to directly target the epigenetic remodeling triggered by
EWSR1-ETS fusions, in hopes of reversing their massive cellular reprogramming. Until
recently, the mechanisms and full extent of EWS-FLI1 epigenetic reprogramming was
unknown (24, 26, 39, 76). These new discoveries paired with the development of highly
effective drugs capable of targeting histone modifications has paved the way for the
development of epigenetic targeted therapies in EWFT. Utilizing these recent discoveries
which have identified the epigenetic mechanisms of EWS-FLI1 gene activation through
histone modifications and chromatin remodeling, we explored a strategy to
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pharmaceutically reverse EWS-FLI1 mediated gene activation. This approach utilized the
indirect inhibition of EWS-FLI1 and demonstrated robust anti-tumor efficacy and is further
discussed in Chapter 4.
Our second approach sought to exploit drug sensitivities acquired during EWSFLI1 genetic reprogramming. One consequence of the EWS-FLI1 fusion is an increase in
DNA-RNA hybrids called R-loops, which are capable of sequestering and inactivating
BRCA1. BRAC1 is critical for the repair of double stranded breaks through its interaction
with RAD51 to influence the repair of DNA and maintain genome stability (56, 94). The
sequestered BRCA1 leads to a deficiency in DNA repair, rendering EWFT acutely
sensitive to DNA damaging agents which have been the focal point of current targeted
therapy research (95-99). In this chapter, we sought a means of re-sensitizing EWFT to a
promising class of DNA damaging agents which, despite the predicated sensitivity, EWFT
tumors were inherently resistant to. Although the mechanisms of these two approaches
differ greatly, they both explore unique therapeutic opportunities of targeting the aberrant
transcription factor which drives EWFT by exploiting flaws in EWS-FLI1 driven
reprograming.
Brenner and colleagues (100) and the Genomics of Drug Sensitivity in Cancer
(GDSC), a high-throughput drug screening platform (101), first demonstrated in 2012 that
EWSR1-FLI1- translocated ES display hypersensitivity to Poly(ADP-ribose) polymerase
inhibition (PARP1i); this has since been replicated by several other groups (98, 99, 102).
These data have provided a promising drug target for EWFTs, with corresponding FDAapproved PARP1 inhibitors (83). However, in the initial clinical study of olaparib in ES,
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no objective responses were observed in 12 evaluable patients (83). While there were no
objective responses, 4/12 patients achieved stable disease, with 2 of the 4 achieving minor
responses (tumor shrinkage of 9% and 12%), indicating a modest level of efficacy via
PARP1 inhibition in these patients.
Based on the hypersensitivity of ES to PARP1i in vitro and signs of activity in ES
patients with olaparib, we sought to identify upfront resistance mechanisms to PARPi
therapy as well as a rational drug combination that could overcome these mechanisms. We
and others have shown that a low apoptotic response, even in the presence of growth arrest,
mitigates response to targeted therapies (87, 103-107). We therefore hypothesized that
mitigated responses of PARPi may be due to loss of apoptotic potential of EWFTs, which
could prove particularly true in the chemo-refractory population. This hypothesis was
further supported by the fact that deficient DNA damage repair is thought to contribute to,
if not define, PARPi sensitivity in ES (99), as well as the established role of anti-apoptotic
BCL-2 family proteins in protecting cancer cells from DNA damage-induced apoptosis
(104, 108) and their inverse correlation of expression to cytotoxic agent sensitivity (8).

Results
A chemotherapy-naive and chemotherapy-resistant cell line pair respond differently
to olaparib
Olaparib performed poorly in ES patients (83) whose tumors were heavily pretreated and chemotherapy-resistant. We therefore utilized a pair of cell lines established
from the same patient prior to and following chemotherapy treatment, at tumor relapse:
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CHLA9 (Children’s Oncology Group), cells were derived from the chemotherapy-naive
PNET, positive for the EWS-FLI1 translocation, whereas the CHLA10 (Children’s
Oncology Group) cell line was established after four cycles of induction chemotherapy
which included cisplatin, doxorubicin, cyclophosphamide and etoposide (109). We first
assessed whether sensitivity to olaparib was different in the two cell lines. We found that
the chemotherapy-naive cells were more sensitive to olaparib, as evidenced by a 5-day
crystal violet viability assay (Fig. 3.1A, left), 72h dose-response curve (Fig. 3.1A, right),
and IC50 curve (Fig. 3.8A) compared to the chemotherapy-resistant CHLA10 cells (Fig.
3.1A), despite both cell lines reportedly expressing high levels of PARP1 (8, 110) and
olaparib inducing similar growth arrest in both the CHLA9 and CHLA10 cells (Fig. 3.8B).
In addition, similar levels of DNA damage was observed following olaparib treatment in
both cell lines as evidenced by pH2A/X immunofluorescence staining (Fig. 3.9A and
3.9B). Furthermore, we confirmed the CHL10 cells were more resistant to chemotherapy
compared to the CHLA9 cells. (Fig. 3.10A and 3.10B).

Chemotherapy-resistant CHLA10 ES cells do not undergo cell death in response to
olaparib
Since the lack of robust apoptotic responses can underlie resistance to both
chemotherapy and targeted therapies, and the apoptotic response following many
chemotherapies and targeted therapies is largely governed by the BCL-2 family of proteins
(103, 106, 111-113), we first explored the relationship between anti-apoptotic BCL-2
family expression and olaparib response in the CHLA9 and CHLA10 models. Expression
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of BCL-2 was upregulated (P < 0.05) in the CHLA10 cells compared to the CHLA9 (Fig.
3.1B and Fig. 3.10C) relative to the sensitive CHLA9 cells, whereas expression of other
key BCL-2 family members were not altered (Fig. 3.1B).
The increase in BCL-2 prompted us to evaluate BCL-2 expression in pre-treatment
and post- chemotherapy biopsy samples from two ES patients treated at our cancer center.
Interestingly, we did not detect an increase in BCL-2 expression in these specimens, in
contrast to the cell line pair, however BCL-XL expression was markedly higher in
chemotherapy-resistant tumors (Fig. 3.1C) relative to the matched chemotherapy-naive
samples. These data indicate that BCL-XL is overexpressed in patients’ ES tumors that
have undergone chemotherapy, and our findings in models of EWFTs implicate BCL-2 as
a cooperating partner with BCL-XL in resisting apoptosis.
Together, these data indicated to us that both BCL-2 and BCL-XL may be
imperative in ES survival. We then moved to chemical interrogation of the cells with
specific BCL-2 family inhibitors. Surprisingly, despite the increase in BCL-2, we found
the BCL-2 specific inhibitor venetoclax (114) was unable to effectively sensitize CHLA10
cells to olaparib (Fig. 3.11A). Since increased expression of BCL-XL is sufficient to induce
resistance to venetoclax (115-117), we next tested the dual BCL-2/BCL-XL inhibitor
navitoclax (118, 119) to determine if this agent sensitizes the CHLA10 cells. While
venetoclax showed little potentiation of olaparib (Fig. 3.11A and 3.11B), navitoclax
sensitized CHLA10 cells to olaparib treatment compared to venetoclax (P < 0.05), leading
to a near complete loss of cell viability (Fig. 3.1D), and showing mild synergy (Fig.
3.11C). Impressively, at low doses of olaparib (1 µM) where there was no single-drug
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efficacy in the CHLA9 cells, the addition of navitoclax led to substantial loss of cell
viability (Fig. 3.11D). Similar to venetoclax, the BCL-XL selective inhibitor A-1331852
(120) was not effective at sensitizing CHLA10 cells to olaparib (Fig. 3.11E). Consistent
with these findings, we found the CHLA9 cells underwent marked cell death in response to
olaparib, as measured by cleaved PARP1 (Fig. 3.1E); in contrast, there was a near absence
of a cell death response in the olaparib-treated CHLA10 cells (Fig. 3.1E). However, the
addition of navitoclax led to marked cleavage of PARP1 in the presence of olaparib in the
CHLA10 cells (Fig. 3.1E), despite the lack of modulation of BCL-2, BCL-XL or the related
MCL-1 (121) by olaparib (Fig. 3.1F).
These data indicate that EWFTs can lose their sensitivity to olaparib following
chemotherapy treatment and relapse, underscored by their inability to undergo cell death,
and can be rescued by the addition of navitoclax. This was further supported by the
observation that, at low concentrations of olaparib where sensitive CHLA9 cells do not yet
respond to single-agent olaparib, navitoclax also sensitizes to olaparib (Fig. 3.11D). "In
addition, the CHLA9 cells have functional p53, while the CHLA10 cells have nonfunctioning p53 (32). It is well established that functional p53 is capable of binding to and
antagonizing the anti-apoptotic functions of BH3 proteins such as BCL-2 and BCL-XL (6,
122). In order to rule out p53 as the cause of inherent resistance to olaparib induced
apoptosis in the CHLA10 cells when compared to the CHLA9 cells, we used siRNA to
knockdown TP53 in the CHLA9 and found no difference in olaparib sensitivity (Fig. 3.11F
left), consistent with a previous report (123). To further support the role of BCL-2 and/or
BCL-XL overexpression in apoptotic resistance to olaparib treatment we overexpressed
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BCL-2 or BCL-XL in the CHLA9 cells. Here, we saw a significant increase in resistance to
olaparib treatment in cells overexpressing BCL-2 or BCL- XL compared to the GFP
controls (P < 0.0001) (Fig. 3.12A). Together these data reveal a striking interplay between
BCL-2/XL inhibition and PARPi in ES.

Navitoclax and Olaparib cooperate to inhibit tumor growth in a CHLA10 mouse
model
We next grew CHLA10 tumors in NSG mice, and evaluated single-agent olaparib,
navitoclax, and the combination of olaparib and navitoclax to see if the in vitro results
would translate in vivo. Consistent with the cell culture experiments (Fig. 3.1D and E), we
found the CHLA10 tumors were not sensitive to olaparib or navitoclax as a monotherapy
compared to their combination (Fig. 3.1G). However, the combination of olaparib and
navitoclax demonstrated robust inhibition of tumor growth (Fig. 3.1G). This contrasted
with the venetoclax/olaparib combination, which was ineffective (Fig. 3.1H), consistent
with the in vitro results (Fig. 3.11A). The olaparib and navitoclax combination did not
induce substantial weight loss in the mice or any overt signs of toxicity, suggesting the
combination is well tolerated (Fig. 3.12B).
To assess possible hematologic toxicity when using olaparib and navitoclax in
combination we performed a complete blood count on NSG mice in vivo. Red blood cell
and reticulocyte counts were not significantly affected by the combination. We did
observe a significant decrease in platelet count as well as neutrophil count following
navitoclax treatment that has previously been reported with its use (114), however,
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importantly, olaparib did not augment platelet loss at either time point. Also of importance,
there was no augmentation of neutropenia or other toxicity by the combination compared
to any single-agent dosing at either time point (Fig. 3.2). As thrombocytopenia is the
major dose limiting effect of navitoclax (124). we also assayed populations of cells
following a 24hr recovery period after 7 days of treatment. Impressively, these mice nearly
fully recovered pre-treatment platelet levels (Fig. 3.2). These data demonstrate olaparib
plus navitoclax may be both effective and tolerated as a novel combination therapy in
EWFTs.

Most ES cell lines do not undergo marked apoptosis following olaparib therapy
Following our findings in the CHLA9 and CHLA10 pair, we next expanded to a
panel of ES cell lines to determine the ability of olaparib to induce apoptosis. A
kin to CHLA10, these cells had poor apoptotic responses to olaparib (Fig. 3.3A), in
contrast to the CHLA9 cells. However, all ES cells underwent G2/M accumulation, as
previously reported (Fig. 3.12C) (96). Caspase 3 activity confirmed both the differential
apoptosis between the CHLA9 cells and other EWFTs lines, as well as the apoptosis
sensitization by navitoclax (3.10A). These data suggest our findings of mitigated apoptotic
responses to olaparib uncovered in the CHLA10 cells extend to other EWFT models.
We next determined whether these other resistant EWFT models had higher levels
of BCL-2 or BCL- XL, as our model would predict. Indeed, in comparison to the CHLA9
cells, these models had higher levels of BCL-2 and/or BCL-XL (Fig. 3.3B), associated with
their poor apoptotic responses to olaparib (Fig. 3.3A). We have uncovered an important
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role for both BCL-2 and BCL-XL in olaparib response in EWFT (Fig. 3.1 and 3.3), and it
would strengthen the case of the importance of BCL-2 and BCL-XL in EWFT survival if
these cancers were sensitive to pharmaceutical targeting of these two proteins. We
therefore examined in the updated GDSC screen (www.cancerRxgene.org) whether ES
cells were more sensitive to navitoclax (Fig. 3.3C) compared to all other solid tumor cell
lines grouped together. In fact, ES cell lines were substantially more sensitive (P=8.69*105

), with 8/21 cell lines demonstrating IC50s of 700nM and below (Fig. 3.3C). To

corroborate the sensitivity to navitoclax, we analyzed MCL1 expression which is capable
of conferring resistance to navitoclax. Examining RNA expression in sarcomas with
translocation events using the R2 platform we found EWS-FLI1 translocated sarcomas
expressed lower levels of MCL1 emphasizing their reliance on BCL2 and BCL2L1 for
survival (Fig. 3.3D).
Interestingly, expression of EWS-FLI1 in HEK293T cells led to higher BCL-2
transcript levels (P < 0.05) compared to the empty vector control, with consistent BCL-2
protein changes (Fig. 3.13B and S3.7C); the FLI1 target genes EZH2 (81), STEAP1, and
PRKCB (22, 125, 126) were all significantly upregulated as well (Fig. 3.13B). To further
evaluate the relationship of FLI1 and BCL-2, we probed the cancer cell line encyclopedia
(90) and found a positive correlation (P < 0.0001) between FLI1 and BCL-2 (Fig. 3.13D);
knockdown of EWS-FLI1 confirmed decrease of BCL-2 expression with the expected
decrease in EZH2 expression (Fig. 3.13E), and de-suppression of the EWS-FLI1 target
LOX, and STEAP1, NPY1R and PRKCB were all downregulated following EWS-FLI1
downregulation, albeit not all significantly (22, 125, 126). Altogether, these data further
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demonstrate the importance of BCL-2 and BCL-XL in EWFTs, which appear to play
complimentary roles, constituting a critical survival signal for EWS-FLI1 driven EWFT.

Navitoclax sensitizes a panel of ES cells to olaparib
We moved to validate navitoclax as a sensitizing agent to olaparib in EWFT cells,
as was determined in the CHLA9 and CHLA10 pair (Fig. 3.1). In fact, we noted marked
sensitization by navitoclax to olaparib-induced apoptosis in a panel of ES cells as
evidenced by cleaved PARP1 (Fig. 3.4A) and FACS measurement of Annexin-V positive
cells (Fig. 3.4B). Consistent with the CHLA pair, apoptosis sensitization was sufficient for
navitoclax to markedly reduce total viable cells as determined by both crystal violet assays
(Fig. 3.4C) and 72h cell-viability assays (Figs. 3.4D and 3.4E). These data again indicate
that olaparib induced apoptosis can be rescued by the addition of navitoclax in ES.

Navitoclax sensitizes ES cells to olaparib by augmentation of DNA damage and
disruption of BIM complexes
We next examined the DNA damaging activity of the olaparib/navitoclax
combination using pH2A/X immunofluorescence staining as a marker for DNA damage.
Interestingly, the DNA damage observed following olaparib exposure was substantially
increased (P < 0.0001) with the addition of navitoclax, which by itself did not induce DNA
damage (Fig. 3.5A and Fig. 3.14A). These data are consistent with a direct role of BCL-2
and BCL- XL in the augmentation of DNA damage (127).
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Navitoclax disrupts BIM:BCL- XL and BIM:BCL-2 complexes, to induce apoptosis
(106, 128-130), and can sensitize kinase inhibitors in different cancers through modulation
of the BCL-2 family (reviewed in ref (36)). We therefore asked whether reduction of BIM
protected from the olaparib/navitoclax combination. As demonstrated in Fig. 3.5B,
reduction of BIM by siRNA led to a concomitant loss in cleavage of PARP1.
Immunoprecipitation of BIM complexes verified navitoclax disrupted BIM:BCL-2
complexes (Fig. 3.5C and Sup. Fig. 3.14B and 3.14C). These data indicate that
olaparib/navitoclax induce apoptosis in EWFTs through disruption of BIM complexes,
whereas this complex disruption leads to BIM-mediated apoptosis (130, 131). Together,
these data demonstrate multiple mechanisms in which navitoclax sensitizes ES to olaparib.

Mouse models of ES are sensitive to Olaparib plus Navitoclax
To robustly test this novel combination of olaparib and navitoclax, we expanded
our analyses to three models of ES; the SK-ES-1 xenograft (ATCC® HTB-86™), and two
patient-derived xenografts (PDXs). Mice were treated daily with olaparib (100mg/kg),
navitoclax (80mg/kg), or the combination of olaparib (100mg/kg) + navitoclax (80mg/kg).
In all three models, there was limited activity of either agent when dosed as a
monotherapy. However, the combination of olaparib and navitoclax markedly inhibited
tumor growth in the SK-ES-1 model and PDX SA10233 and, impressively, almost
completely shrank tumors in the other PDX model, SA13542 (Fig. 3.6A and 3.6B). Again,
the combination did not markedly affect mouse weights or induce any overt signs of
toxicity (Fig. 3.12B). Assessment of the tumor lysates from the PDX confirmed marked
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apoptosis induction with the combination, but not single-agents (Fig. 3.6C), and that both
PDX models expressed BCL-XL and with the SA10233 model expressing high levels of
BCL-2 (Fig. 3.14D) confirming RNA sequencing data on BCL2 mRNA expression levels
between the two PDX models (SA10233 3.5045, SA13542 0.672) . These data, along with
the CHLA10 chemorefractory mouse model (Fig. 3.1G), demonstrate compelling activity
of the combination of olaparib and navitoclax in vivo.

Discussion
Through an unbiased high-throughput drug screen, olaparib was discovered to have
marked in vitro activity in ES (101). Despite several reports demonstrating hypersensitivity
of ES to PARP1 inhibition (8, 98-100, 102, 132), subsequent clinical evaluation in a
heavily pre-treated cohort of ES patients with single-agent olaparib showed only modest
efficacy (83). Here, we demonstrated an important role for deficient apoptosis following
olaparib therapy in ES, with the anti-apoptoticproteins BCL-2 and BCL-XL playing key
roles. We believe these experimental findings at least in part explain the disappointing
clinical data.
PARP inhibitors prevent single-stranded (ss) DNA break repairs. This mechanism
underlies PARPi activity in BRCA-deficient cancers, which are inherently deficient in
double-stranded (DS) DNA break repair (94). In ES, PARPi sensitivity has been proposed
to occur for several reasons: First, PARP1 expression is higher in Ewing sarcoma (133),
probably as a direct result of EWS-FLI1 (100, 133), and higher PARP1 expression is a
cause of enhanced PARP inhibitor sensitivity (134), most likely through the mechanism of
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PARP trapping at ssDNA breaks (135-137). Second, ES, like BRCA- deficient cancers,
appear to have a deficient dsDNA repair system (99). Third, FLI1 drives high SLFN11
expression (138), a gene tightly linked to DNA-damaging agent efficacy (90, 139). Fourth,
EWS-FLI1 expression is sufficient to increase dsDNA breaks (100). Fifth, EWS-FLI1
causes R-loop accumulation, increased replication stress and interferes with BRCA1
function (56).
Although there are several factors that may have contributed to olaparib’s lack of
efficacy in patients with chemotherapy-resistant ES, it is likely that a biological resistance
mechanism served to rescue tumor cells from direct PARP inhibition. We propose that
there is an inherent deficiency in many ES to undergo apoptosis following olaparib
treatment resulting from a protective effect of BCL-2 and BCL-XL (Fig. 3.1 and Fig. 3.3).
Furthermore, exposure and resistance to chemotherapy appears to contribute to this state of
apoptotic resistance to olaparib, as evidenced by our results in the CHLA10 cell line (Fig.
3.1E and 3.3A) and observations in patients’ tumor specimens (Fig. 3.1C). It is likely that
DNA damaging agents used in induction chemotherapy lead to additional pressure on the
ES tumor and, as a result, the emergence of cells particularly reliant on BCL- 2/BCL-XL
for survival. Overall, further studies will be necessary to elucidate the precise relationship
between these pro-survival BCL-2 members and ES tumorigenesis.
The strategy to sensitize ES to PARPi via BCL-2/BCL-XL co-inhibition is different
from other explored strategies to sensitize ES to PARPi; these include the addition of DNA
damaging agents that intensifies the amount of active DNA damage in the cell, like
irinotecan and temozolomide (102). Temozolomide has also been demonstrated to enhance
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PARP1 trapping (137) and, interestingly, the combination of temozolomide and PARPi
cooperatively downregulates MCL-1, sensitizing to mitochondrial-mediated death (102).
Although temozolomide-PARPi combinations are poorly tolerated in preclinical ES mouse
models (99), irinotecan delivered to an orthotopic ES mouse model in dosing schedules
consistent with the pediatric population demonstrated marked activity (99). Consistent with
these results, the combination of the PARPi veliparib and irinotecan was well tolerated in a
recent phase I trial, including reaching a dose sufficient for PARP inhibition in adult
cancers (140). Interestingly, BCL-XL blocks the ability of irinotecan to induce apoptosis
and BCL-XL inhibition results in a switch from irinotecan-induced senescence to apoptosis
(141). Therefore, it is possible that PARPi/irinotecan combinations in other ES models will
face the same issues we have found PARPi monotherapy to face, namely a refractory
apoptosis response. The PARPi/irinotecan combination is currently being evaluated in
pediatric patients with solid tumors (NCT02392793).
The BCL-2 family of proteins monitors the integrity of the mitochondria and
integrates the signals of many pathways at the mitochondria (142). Importantly, Javaheri
and colleagues (59) elegantly demonstrated that EWS-FLI1 overexpression in
mesenchymal stem cells, the presumed cell of origin for ES, was sufficient for blocking
differentiation but led to high rates of apoptosis; retrovirus containing BCL-2, BCL- XL or
MCL-1 expression plasmids was able to rescue apoptosis, and importantly, led to sarcoma
formation, which was not accomplished in the parallel, control transduced cells. These data
together with the data in this manuscript present a compelling case where anti-apoptotic
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activity of BCL-2 family members, particularly BCL-2 and BCL- XL, play an intricate role
in ES tumorigenesis and impact ES therapy.
It has been well known for several decades that BCL-2 has a protective role against
DNA damage-induced apoptosis (127, 143). Additionally, BCL-XL expression has been
reported tocorrelate inversely with the sensitivity of cancer cell lines to multiple anti-tumor
agents, including those acting via a DNA-damaging mechanism (8). This becomes
particularly relevant in the light that ES have deficient DNA damage responses (99).
Adding to the intrigue, Khan and colleagues recently reported 13% of patients with ES
have germline loss-of-function mutations in DNA repair genes (95). It is therefore
tempting to speculate that, in order for EWS-FLI1- translocated ES to develop and thrive,
there must be an acquired reliance on the anti-apoptotic proteins BCL-2 and BCL-XL to
maintain survival. Consistent with this notion, our analyses of HTS data revealed
navitoclax has substantial single-agent activity (IC50 less than 700nM) across ~40% of ES
cell lines (Fig. 3.3C).
This notion is further supported by our findings in the CHLA cells derived from a
patient prior to and following chemotherapy treatment. The post-chemotherapy CHLA10
cells, derived at progressive disease, had higher BCL-2 expression relative to the matched
chemotherapy-naive CHLA9 cells (Fig. 3.1B) and, unlike CHLA9 cells, failed to undergo
cell death following olaparib therapy (Fig. 3.1E and 3.3A). It is important to note that we
did not account for other changes that occurred during the acquisition of chemotherapy
resistance in this model, which could contribute to the resistance of these cells to olaparib.
For instance, Sorensen and colleagues demonstrated the CHLA10 cells have enhanced flux
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compared to the CHLA9 cells through the PI3K pathway, which is a result of increased
ErbB4 expression (144) and which may be contributing to olaparib resistance.
Notwithstanding, the fact that navitoclax was sufficient to re-sensitize the cells to olaparib
reflects the importance of BCL-2 and BCL-XL. Interestingly, in the chemotherapy-naive
CHLA9 cells, where olaparib was very effective (Fig. 3.1A), navitoclax fully sensitized
these cells to a low dose of olaparib (Fig. 3.11D), which did not have marked single agent
anti-cancer activity. These data reveal an important interplay between PARP inhibition and
BCL-2/XL inhibition, which likely contributes to the impressive activity of dual PARP and
BCL-2/XL inhibition in ES (Figures. 3.1, 3.3 and 3.4), and, again, supports the notion that
BCL-2 and BCL-XL are important to counteract the intrinsic deficiencies in ES DNA
damage repair, which are exacerbated by PARP inhibition. Indeed, BCL-2/BCL- XL
inhibition causes accumulation of DNA damage following PARP inhibition (Fig. 3.9A and
Fig. 3.13A). Therefore, the robust activity of PARP inhibition and navitoclax is most likely
due to both BCL-2 and BCL- XL inhibition making these cells more vulnerable to DNA
damage-induced apoptosis, but also increasing the DNA damage itself. The result is a
substantial increase in apoptosis (Fig. 3.4A-B), mediated by BIM (Fig. 3.5B and 3.5C),
which translates to impressive in vivo activity.
Overall, we demonstrate ES tumors do not undergo a marked apoptotic response
following olaparib therapy; however, co-targeting BCL-2 and BCL-XL dramatically
sensitizes these tumors to olaparib in several mouse models of ES, including
chemotherapy-resistant ES and two PDX models of ES. As we found neither drug
augmented hematological toxicity of the other (Fig. 3.2), and rational navitoclax-based
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combinations with other targeted therapies are ongoing in clinical trials (e.g.
NCT02520778), evaluation of PARP inhibitors and navitoclax in ES are warranted.
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Figure 3.1 Chemotherapy-resistant EWFT are sensitized to olaparib with the Inhibition of
BCL-2 and BCL- XL
(A) (left) Crystal violet staining of CHLA9 and CHLA10 after 5-day treatment showing
sensitivity to no treatment control (no rx) or 5 µM olaparib. (145) 72 hour CellTiter Glo of
CHLA9 and CHLA10 using the indicated concentrations of olaparib. (B) Western blot
analysis of the indicated antibodies in chemotherapy-naive and chemotherapy-resistant
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Figure 3.1 continued
paired lines. (C) Two cases of Ewing sarcoma with available paired primary and recurrent
metastatic tissues were immunostained for BCL-2 and BCL-XL. In both cases, similar
expression of BCL-2 was noted in primary. For BCL-XL, however, increased expression
was noted in both recurrences compared to the primary tumor. Case 1: Primary: Archival
sections of the untreated biopsy of the primary tumor (patella), which was localized at
presentation. Recurrence: Lung metastasis 5 years subsequent, after systemic
chemotherapy (VAC-IE) and localized radiotherapy to the patellar primary site. Case 2:
Primary: Archival sections of the biopsy of the untreated primary tumor (thoracic spine),
which was metastatic (rib, lung, bone marrow) at presentation. Recurrence: Bone
metastasis (right humerus) 8 months subsequent, after systemic chemotherapy (VAC-IE)
and localized radiotherapy to the primary and multiple metastatic sites. (D) Crystal violet
staining showing olaparib resistant CHLA10 cells after 5-day treatment with no treatment
control (no rx), 5 µM olaparib, 1 µM navitoclax or the combination of 5 µM olaparib + 1
µM navitoclax. (E) Western blot analysis of apoptosis indicated by an increase in cleaved
PARP1 in CHLA9 and CHLA10 cells after 24 hour treatment with no treatment control
(no rx), 5 µM olaparib, 1 µM navitoclax, or 5 µM olaparib + 1 µM navitoclax. (F) Western
blot analysis of the indicated antibodies in the CHLA9 and CHLA10 cell lines after 24
hour treatment with no treatment control (no rx), 5 µM olaparib, 1 µM navitoclax, or 5 µM
olaparib + 1 µM navitoclax. (G) CHLA10 xenografts treated daily with olaparib
(100mg/kg), navitoclax (80mg/kg), or the combination of olaparib (100mg/kg) +
navitoclax (80mg/kg) for 28 days. Error bars are +SEM. Asterisks indicate a significant
separation between the combination (olap/nav) and all other treatment cohorts using the
student’s t test (P < 0.05) (H) CHLA10 xenografts treated daily with olaparib (100mg/kg),
venetoclax (100mg/kg), or the combination of olaparib (100mg/kg) + venetoclax
(100mg/kg) for 27 days. Error bars are +SEM

45

Figure 3.2 Combination of olaparib and navitoclax does not augment toxicity
(A) NSG mice were treated with a no treatment control (no rx), olaparib (100mg/kg),
navitoclax (80mg/kg), or the combination of olaparib (100mg/kg) + navitoclax (80mg/kg).
After the indicated 3 or 7 day treatment period, blood was collected and sent to IDEXX
BioResearch (idexxbioresearch.com) for a complete blood count. The recovery cohort was
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Figure 3.2 continued
treated for 7 days with the combination of olaparib (100mg/kg) + navitoclax (80mg/kg)
and allowed 24 hours without treatment before blood was collected. Asterisks indicate a
significant separation between 7 day treatment with olaparib + navitoclax and 7 day
recovery using the Student’s t Test (P<0.05). 3 day treatment with navitoclax not
significant compared to 3 day treatment with the combination olaparib + navitoclax,
neither was 7 day navitoclax compared to 7 day olaparib + navitoclax.
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Figure 3.3 EWFT are resistant to olaparib which correlates with increased BCL-2 and
navitoclax sensitivity
(A) FACS analysis of apoptosis after 24 hour treatment with 5 µM olaparib. Error bars are
+SEM. Asterisks indicate a significant separation between olaparib treatments in the
CHLA10 cells compared to CHLA9 cells, using the student’s t test (P < 0.05) (B) Western
blot analysis of the indicated antibodies in EWFT cell lines. (C) IC50 of navitoclax plotted
for solid tumor cell lines and 21 Ewing Sarcoma cell lines from
http://www.cancerrxgene.org/. A Mann-Whitney non-parametric test was performed
(P=8.69*10-5) (D) ) MCL-1 RNA expression in sarcomas with translocation events (34).
.
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Figure 3.4 Combination of olaparib and navitoclax is effective in multiple EWFT cell lines
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Figure 3.4 continued
(A) Western blot analysis of apoptosis indicated by cleaved PARP1 after 24 hour treatment
with no treatment control (no rx), 5 µM olaparib, 1 µM navitoclax, or 5 µM olaparib + 1
µM navitoclax. (B) FACS analysis of apoptosis after 24 hour treatment with 5
µM olaparib, 1 µM navitoclax, or 5 µM olaparib + 1 µM navitoclax. Percent of apoptosis
induced by drugs is normalized to the no treatment control. Error bars are +SEM. (C)
Crystal violet staining after 5-day treatment with 5 µM olaparib, 1 µM navitoclax, or 5 µM
olaparib + 1 µM navitoclax. (D) Dose response curves in ES cell lines after 72 hour
treatment with increasing concentrations of olaparib. Viability was determined using
CellTiter-Glo. Data is graphed as percent viable cells from no treatment control (no rx),
performed in quadruplicate. Error bars are +SEM. (E) ES cell lines after 72 hour treatment
with 1 µM navitoclax or 1 µM navitoclax in the presence of increasing concentrations of
olaparib and viability was determined using CellTiter-Glo. Data is graphed as percent
viable cells from no treatment control (no rx), performed in quadruplicate. Error bars are
+SEM.
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Figure 3.5 DNA damage is increased with the combination of olaparib and navitoclax
(A) Quantification of immunofluorescence images probed for γH2A.X foci intensity
following 24 hour treatment using no treatment control (no rx), 5 µM olaparib, 1 µM
navitoclax, 5 µM olaparib + 1 µM navitoclax or 1 µM etoposide. Error bars are +SEM.
Asterisks indicate a significant separation between olaparib treatment and the combination
olaparib + navitoclax. Significance was determined using the Mann-Whitney U test. (B)
siRNA knockdown of BIM or control (scramble sequence) in ES4 and A673 cell lines
followed by 24 hour treatment with either no treatment control (no rx) or 5 µM olaparib +
1 µM navitoclax (Nav/Olap). (C) An immunoprecipitation of lysates from A673 cells using
either a BCL-2 antibody or an IgG control antibody (left) and the whole cell lysates (5%
input) (145), after 4 hour treatment with 5 µM olaparib, 1 µM navitoclax, or 5 µM olaparib
+ 1 µM navitoclax.
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Figure 3.6 Olaparib and navitoclax combination is effective in Mouse Models of EWFT
(A) SK-ES-1 xenografts treated daily for 26 days (top) and patient-derived xenografts
(bottom) treated daily for 31 days (PDX SA13542) or 27 days (PDX SA10233) with
olaparib (100mg/kg), navitoclax (80mg/kg), or the combination of olaparib (100mg/kg) +
navitoclax (80mg/kg). Error bars are +SEM. Asterisks indicate a significant separation
between the combination (olap/nav) and all other treatment cohorts using the student’s t
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Figure 3.6 continued
test (P < 0.05) (B) Fold change in tumor volume, please note data is from the experiment
shown in Fig. 4A (PDX SA13542) after 31 days of treatment and the x axis denotes
individual xenografts. (C) Western blot analysis of cleaved PARP1 from PDX tumor
lysates after 3 daily treatments of no treatment control (no rx), olaparib (100mg/kg),
navitoclax (80mg/kg) or the combination of olaparib (100mg/kg) + navitoclax (80mg/kg).

53

Figure 3.7 Melting Curves
(A) Indicated primer melting curves taken from 293T EWS-FLI1 expressing cells during
RT-qPCR
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Figure 3.8 A chemotherapy-naive and chemotherapy-resistant cell line pair respond
differently to olaparib
(A) IC50 curve of CHLA9 and CHLA10 cells following 72 hour treatment with the
indicated concentrations of olaparib. (B) Cell cycle analysis after 24, 48 and 72 hour
treatment with 5 µM olaparib, compared to no drug treatment control (No Rx).
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Figure 3.9 Olaparib induces similar levels of DNA damage in CHLA9 and CHLA10
(A) Representative immunofluorescence images showing γH2A.X foci following 72 hour
treatment of 5 µM olaparib compared to no treatment control (No Rx). (B) Quantification
of immunofluorescence images probed for γH2A.X intensity following 72 hour treatment
of 5 µM olaparib compared to no treatment control (No Rx). Error bars are +SEM,
asterisks indicate significance between the no treatment control and olaparib treatment for
CHLA9 or CHLA10, as determined using the Mann-Whitney U test.
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Figure 3.10 A chemotherapy-naive and chemotherapy-resistant cell line pair respond
differently to chemotherapeutics
(A) CellTiter Glo of CHLA9 and CHLA10 cells after 72 hour treatment with increasing
concentrations of Etoposide and Doxorubicin. Data is graphed as percent viable cells from
no treatment control, performed in quadruplicate. Errors bars are +SEM. (B) IC50 curves
representing the data collected in (A). (C) Quantification of BCL-2 protein expression
represented in Figure 1B, (n=3). Asterisk indicates a significant separation between
CHLA9 and CHAL10 BCL-2 protein expression, and significance was determined using
the Student’s t test (P < 0.05).
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Figure 3.11 Navitoclax sensitizes EWFT to olaparib
(A), (B) CellTiter-Glo of CHLA10 (A) and CHLA9 (B) cells after 72 hour treatment with
1 µM venetoclax or 1 µM navitoclax with increasing concentrations of olaparib. Data is
graphed as percent viable cells from no treatment control, performed in quadruplicate.
Error bars are +SEM. Asterisks indicate a significant separation between the indicated
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Figure 3.11 continued
concentrations of venetoclax + olaparib compared to navitoclax + olaparib. Significance
was determined using the Mann-Whitney U test. (C) (left) CellTiter Glo viability after 24
hour treatment with the indicated concentrations of olaparib and navitoclax. (145) Percent
over the bliss score. Positive scores (red) indicate synergy, negative scores (blue) indicate
antagonism. All concentrations are presented as µM. (D) Crystal violet staining after 5 day
treatment showing sensitivity to the indicated drug treatments (E) FACS analysis of
apoptosis in CHLA10 cells after 24 hour treatment with 1 µM of the BCL-XL inhibitor A1331852, 5 µM olaparib, 5 µM olaparib + 1 µM A-1331852, 1 µM navitoclax, or 5 µM
olaparib + 1 µM navitoclax. Percent of apoptosis induced by drugs is normalized to the no
treatment control (No Rx). Error bars are +SEM. Asterisks indicate a significant separation
between navitoclax and olaparib + navitoclax. There was no significance between the A1331852 treatment compared to olaparib + A-1331852. Significance was determined
using the Student’s t Test (P<0.05). (F) (left) CellTiter Glo analysis after 72 hour treatment
with the indicated olaparib concentrations in CHLA9 cells expressing siScramble or
siTP53. Error bars are +SEM and there is no significance. (145) Western blot analysis
confirming siRNA knockdown of p53 protein in CHLA9 cells.
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Figure 3.12 Olaparib sensitivity is modulated by BCL2 family expression
(A) (left) Western blot analysis of BCL-2 and BCL-XL, confirming over expression in
CHLA9 cells. (145) CellTiter Glo assay after 24 hour treatment with 5 µM olaparib in
CHLA9 cells over expressing GFP, BCL-2, or BCL-XL. Asterisks indicate a significant
separation between the GFP control, and BCL-2 cells treated with olaparib or BCL- XL
cells treated with olaparib. Student’s t test was performed. (B) Average measurement of
mouse weight (grams) per condition (n=5 mice or greater per condition) over the course of
each in vivo experiment. Please note, this data was obtained from the efficacy experiments
shown in Fig. 1F and Fig. 4A, respectively. (C) Cell cycle analysis after 24 hour treatment
with 5 µM olaparib in the indicated cell lines, compared to no drug treatment controls cells
(No Rx).
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Figure 3.13 EWS-FLI1 increases BCL-2 expression in EWFT
(A) Cleaved Caspase-3 activity after 24 hour treatment with the indicated drugs: 5 µM
olaparib, 1 µM navitoclax, or 5 µM olaparib + 1 µM navitoclax, compared to no treatment
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Figure 3.13 continued
control (No Rx). Activity is presented as Relative Fluorescent Units (RFU). Experiments
were performed in quadruplicate and error bars are plotted as +SEM. Asterisks indicate a
significant separation between the no treatment control and each individual treatment.
Significance was determined using the Student’s t Test. (B) RNA expression of the
indicated genes in pl4-EWS-FLI1 or pl4-Empty Vector expressing 293T cell lines.
Asterisks indicate a significant separation between the empty vector control and the EWSFLI1 expressing cells and was determined using the Student’s t Test. (C) Western blot
comparison as detected by the indicated antibodies in pl4-EWS-FLI1 and pl4-Empty
Vector 293T cell lines. (D) BCL-2 RNA expression from the (CCLE) in high (n=208) and
low (n=829) FLI1 expressing tumors. Individual cell lines are represented by a single dot.
A Mann-Whitney non-parametric test was performed for significance. (E) RNA expression
of the indicated genes after shRNA knockdown of EWS-FLI1 or control (scramble
sequence) in A673 and EW16 cell lines. Asterisks indicate a significant separation between
the shScramble control and the EWS-FLI1 knockdown cells, significance was determined
using the Student’s t Test.
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Figure 3.14 DNA damage is increased with the combination of olaparib and navitoclax
(A) Representative immunofluorescence images showing γH2A.X foci following 24 hour
treatment 5 µM olaparib, 1 µM navitoclax, 5 µM olaparib + 1 µM navitoclax,1 µM
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Figure 3.14 continued
etoposide (serving as a positive control), or no treatment control (No Rx). (B)
Densitometry quantification of BCL-2 levels from the whole cell lysates in Fig. 5C
normalized to GAPDH. (C) Western blot analysis with the indicated antibodies after 24
hour treatment of 5 µM olaparib, 1 µM navitoclax, 5 µM olaparib + 1 µM navitoclax or no
treatment control (No Rx). (D) Tumor lysates from control PDX and cell line xenograft
models were analyzed by Western blot with the indicated antibodies.
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Chapter 4 – Pharmaceutical Means of Targeting the Fusion Oncogene EWS-FLI1 in
the Ewing Family of Tumors

Introduction
Pediatric cancers often have a low mutation burden which suggests epigenetic
mechanisms may play major roles in driving tumorigenesis (146). It is well known that
EWS-FLI1 induces a myriad of epigenetic changes, including global increases in H3K27ac
a marker for enhanced gene activation, which was the most highly regulated histone mark
following exogenous EWS-FLI1 expression in mesenchymal stem cells (the potential cell
of origin for EWFT), including within enhancer regions bound by FLI1 (24, 26, 39, 67).
This would suggest EWS-FLI1 driven changes in H3K27ac are responsible for the
activation of FLI1 target genes. In the same study it was found that H3K27 methylation
(H3K27me) did not associate with EWS-FLI1 binding, and it is evident that altering
H3K27me has an inactivating effect on H3K27ac marked gene targets (147, 148).
We have uncovered an effective therapeutic strategy to target the EWS-FLI1
program by exploiting a hypersensitivity to the inhibition of H3K27 demethylases using a
high-throughput pharmacological screen (13). We demonstrate that H3K27 demethylase
inhibition is synergistic with RNAP II inhibition, effectively blocking EWS-FLI1 gene
target activation and resulting in strong anti-EWFT activity.
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Results
Drug screen reveals hypersensitivity of EWFT cell lines to GSK-J4
Utilizing the Genomics of Drug Sensitivity in Cancer (GDSC) platform (13) in a
high-throughput drug screening, it was revealed that EWFT are acutely sensitive to GSKJ4 an H3K27 demethylase inhibitor (Fig. 4.1A). Of the ~900 solid tumor cell lines tested,
21 were EWFT. Of those EWFT cell lines tested, 12/21 were among the top 25% most
sensitive and 17/21 were among the top 50% most sensitive cell lines. GSK-J4 targets the
histone 3 Lysine 27 demethylases: Ubiquitously transcribed tetratricopeptide repeat, X
chromosome (UTX), and Jumonji D3 (JMJD3) described in Figure 4.1B. Upon further
investigation, we found no correlation between GSK-J4 sensitivity and expression of its
targets KDM6A (UTX)) and KDM6B (JMJD3), nor was there any correlation with the
enhancer of zeste homolog 2 (EZH2) (80, 81, 149-151) or other members of the
polycomb2 repressor complex (PRC2) (data not shown). Interestingly we found an inverse
correlation between overall survival and the expression of KDM6B (152, 153), linking
higher expression to lower overall survival (Fig. 4.1C), and emphasizing its relationship
with EWFT severity.

GSK-J4 inhibits EWFT growth in vitro by downregulating EWS-FLI1 targets
To fully characterize the sensitivity of EWFT to GSK-J4 we assessed its activity in
a panel of EWFT cell lines. GSK-J4 treatment reduced cell viability in a dose dependent
manner (Fig. 4.2A) in 72-hour cell viability assays. We found chemical interrogation with
GSK-J4 had a robust effect on EWFT cell lines including a near complete loss of cell
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viability in 5-day clonogenic assays (Fig. 4.2B). To ensure on-target specificity of GSK-J4
we utilized western blotting to analyze global histone modifications in cell lines treated
with GSK-J4 and found, as expected, a subsequent increase in global levels of H3K27 trimethylation after treatment with GSK-J4 (Fig. 4.2C). H3K27 methylation and acetylation
are closely linked in balancing gene expression, and a loss of H2K27 methylation allows
for acetylation at the same regions (92, 147, 148, 154-156). For example, in H3K27M
mutant diffuse intrinsic pontine glioma (DIPG), which has a reduced H3K27me3 levels,
there are marked increases in H3K27ac (157, 158). We found the addition of GSK-J4 led
to global increases in H3K27me3 coupled with a subsequent decrease in H3K27ac (Fig.
4.2C), while other key histone modifications were unaffected (data not shown). This
suggests GSK-J4 is able to shift global Histone 3 Lysine 27 epigenetic regulatory marks
from a highly active to an inactive state and is verified by a decrease in the expression of
bona fide EWS-FLI1 target EZH2 (Fig 4.2C) (80, 81).
Using annexin V/propidium iodide staining we assessed the ability of GSK-J4 to
induce apoptosis in cells using shRNA to knockdown EWS-FLI1. We found EWS-FLI1
reduction significantly diminished the ability of GSK-J4 to induce cell death (Fig. 4.2D),
demonstrating that EWS-FLI1 expression is responsible for sensitizing cells to the
pharmaceutical inhibition of UTX/JMJD3.
The EWS-FLI1 translocation is a strong driver of H3K27ac modifications which
results in gene upregulation (24, 76), therefore we investigated the global expression levels
of several well characterized EWS-FLI1 target genes: cyclin d1 (CCND1) (39), EZH2, and
neuropeptide Y receptor Y1 (NPY1R) (24, 26, 97, 159). Western blot analysis indicates a
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strong downregulation of the protein levels for these three genes following GSK-J4
treatment (Fig. 4.3A). Transcript levels were also markedly decreased after the same
GSK-J4 treatment conditions (Fig. 4.3B). Using this data, we hypothesize that the
H3K27ac marks which can be reduced by GSK-J4 chemical interrogation might overlap
with those of EWS-FLI1 target gene enhancers, suggesting an epigenetic means of indirect
EWS-FLI1 inhibition.

GSK-J4 is effective and tolerable in multiple PDX models of EWFT
To assess the activity of GSK-J4 in vivo we utilized several PDX models derived
from relapsed EWFT patients (160).

GSK-J4 given once a day (50mg/kg/qd) by

intraperitoneal injection demonstrated marked anti-tumor activity and was sufficient to
control tumor growth in all four PDX models (Fig. 4.4A). Body weight measurements
indicated no overt signs of toxicity in the mice (weight loss >15% or behavioral changes),
as demonstrated in Figure 4.4B. This highlights the single agent efficacy of GSK-J4 as a
therapy tailored for EWFT and advocates H3K27 demethylase inhibition as a potential
candidate to test in combination therapy.

CDK7 inhibition sensitizes EWFT to GSK-J4
Despite the in vivo efficacy of GSK-J4 as a single agent in refractory PDX models
(Fig. 4.4) we want to enhance the dose response and prevent the possibility of acquired
drug resistance by using GSK-J4 as a combination therapy. We have recently
demonstrated that targeting cyclin dependent kinases (CDK) can inhibit transcription in
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cancer (161), and often sensitizes to additional therapies (162-164). It has been well
documented that the inhibition of transcription is a highly effective treatment in several
cancer types, and that the EWFTs are sensitive to the very selective CDK7 inhibitor THZ1
(165, 166), which blocks RNA polymerase II (RNAP II) phosphorylation at serine 5. We
rationalize that the use of THZ1 to prevent RNAP II activation would prove a viable drug
target, working synergistically with GSK-J4 to inhibit EWS-FLI1 driven transcription.
CDK7 specific inhibitors are well characterized and have shown preferential suppression
of super-enhancer marked genes (167), which would suggest specificity towards EWSFLI1 driven transcripts.
To assess this hypothesis, we utilized THZ1 in combination with GSK-J4 to
calculate Bliss Independence dose-response models (91). We found strong synergy among
multiple EWFT cell lines as well as four of our ex vivo derived PDX lines (Fig. 4.5A) and
notably, the combination was effective at concentrations that demonstrated little single
agent activity. The observed synergy at concentrations with limited or no single agent
efficacy suggests concentrations of THZ1/GSK-J4 may be used in combination at lower
concentrations than those required by single agent treatment for similar efficacy. Western
blot analysis further supports this notion as indicated by high expression of cleaved PARP1
in the combination, paired with marked reduction in global H3K27ac (Fig. 4.5B).

CDK7 inhibition combines with GSK-J4 to cooperatively downregulate EWS-FLI1
targets

69
To better characterize the mechanisms of sensitivity and specificity towards EWSFLI1 gene target regulation, we performed chromatin immunoprecipitation against
H3K27ac in the A673 cell line and designed primers flanking the FLI1 binding site of
several EWS-FLI1 target gene enhancers. Consistent with the histone modifications in
Figures 4.2C and 4.5B, we found GSK-J4 treatment induced a significant downregulation
of H3K27 acetylation at putative FLI1 bound enhancers elements (Fig. 4.6A). We found
that the well characterized FLI1 target genes NPY1R, EZH2 (26, 69), and NKX2.2 (168)
had significantly less H3K27ac histone marks at their putative enhancer sites upon
treatment with GSK-J4 and THZ1 compared to unmodified EWFT no treatment controls,
which correlates with the global protein changes described in Figures 4.2C and 4.5B .
These results correlate with RNA transcript levels following the same drug treatments.
This data further supports our hypothesis that disrupting UTX/JMJD3 activity functions as
an indirect inhibitor of EWS-FLI1 through the reversal of H3K27 acetylation at EWS-FLI1
driven genes.

THZ1 and GSK-J4 combine to induce anti-EWFT activity in vivo
We next sought to evaluate the combination of GSK-J4 and THZ1 in our SA10233
PDX model of EWFT. Daily treatment with GSK-J4 (50mg/kg/qd) and THZ1
(10mg/kg/qd) was sufficient to reduce tumor growth in a controlled manner compared to
the vehicle and single agent groups (Fig. 4.6B and 4.6C). In the combination cohort, some
toxicity was detected with decreases in weight recorded during the final two data collection
timepoints.
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Discussion
The Ewing Family of Tumors is defined by EWS/ETS translocations which drive
tumorigenesis (20, 123). The most abundant translocation being EWS-FLI1 which
initiates transcriptional reprograming, resulting in a loss of tumor suppressors and the
activation of oncogenes (24, 76, 169). Despite the promising therapeutic opportunity that a
single driver event presents, successful targeting of the EWS-FLI1 transcription factor
remains elusive.
Recent studies have shown that EWS-FLI1 drastically alters the epigenome and
emphasis has been placed on targeting histone modifications as an effective anticancer
therapy. Several targeting strategies are currently being investigated which seek to reverse
specific epigenetic dysregulations caused by EWS-FLI (80, 169-173). Parrish and
colleagues (174) recently demonstrated that the pan-Jumonji-domain histone demethylase
inhibitor JIB-04 can dysregulate the EWS-FLI1 oncogenic program. However, pan
Jumonji histone demethylase inhibition results in the upregulation of H3K4me3 (through
the inhibition of Lysine Demethylase 5A) which is associated with increased transcription
and can lead to the expression of not only tumor suppressors but oncogenes, possibly
diminishing its effectiveness. Similarly, the Lysine-specific histone demethylase 1
(LSD1/KDM1A) is also responsible for demethylating H3K4, and EWS-FLI1 utilizes
LSD1 overexpression to silence tumor suppressors. The use of LSD1 inhibitor HCI2509 is
currently being investigated as a potential therapy for EWFT (175).
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Another approach to target the EWFT epigenome has focused on increasing
H3K27ac using histone deacetylase (HDAC) inhibitors. This can lead to growth arrest and
promote differentiation in EWFT, and has a rescuing effect on tumor suppressors which
are downregulated by EWS-FLI1 (169, 173). While these strategies prove the efficacy in
reversing epigenetic changes caused by EWS-FLI1, they focus on rescuing tumor
suppressor expression and fail to address H3K27ac mediated activation of oncogenes,
which are the histone mark most highly regulated by EWS-FLI1 (76).
Targeting the histone demethylases UTX/JMJD3 causes the accumulation of
H3K27me3 and results in gene repression. This strategy differs from other EWFT
epigenetic therapies currently under investigation, which seek to inhibit HDAC or increase
H3K4me3 levels to promote the re-expression of tumor suppressors. Our approach differs
by silencing EWFT oncogenes directly and does not rely on tumor suppressor function. In
fact, HDAC and KDM5A/LSD1 inhibitors have the drawback of promoting oncogene
expression in addition to tumor suppressors, putting the cells at a disadvantage.
H3K27me3 accumulation does not rescue tumor suppressor expression, however it serves
to function as surrogate tumor suppressors by preventing oncogene expression,
diminishing the need for tumor suppressor reactivation. Despite the effectiveness of GSKJ4, there remains both a lack of reliable biomarkers to predict its clinical activity and the
potential for EWFT to become resistant. We hope that by utilizing the CDK7 inhibitor
THZ1 in combination, we can mitigate the development of GSK-J4 resistance.
In summary, we have uncovered an effective therapeutic strategy to epigenetically
target the EWS-FLI1 program resulting in reduced FLI1 target gene expression (Fig. 4.7).
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By inhibiting UTX/JMJD3 in combination with CDK7 inhibition we are able to both drive
H3K27 modifications towards hypermethylation, subsequently reducing H3K27ac
activation of EWS-FLI1 targets, and block RNAP II mediated transcription of those same
genes. Our studies highlight an effective and promising new epigenetic therapy for the
treatment of EWFT, however further work is required to support the mechanistic
relationship and to elucidate the clinical efficacy of these drugs in combination.
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Figure 4.1 Drug Screen reveals sensitivity of EWFT to GSK-J4
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Figure 4.1 Continued
(A) High throughput screen of GSK-J4 measuring viability with resazurin, in collaboration
with the GDSC. (B) Graphical representation of GSK-J mechanism, directly targeting the
histone demethylases JMJD3 and UTX, which are responsible for removing methyl groups
in opposition to the PRC2 complex. Drug treatment results in global increases in H3K27
methylation. (C) Survival Analysis of EWFT patients with KDM6B high and low
expression from the Gene Expression Omnibus GSE17679. Statistical analysis was
performed using the log-rank test.
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Figure 4.2 GSK-J4 reduces cell viability and alters H3K27 marks in EWFT
(A) 72-hour dose response viability assay with increasing concentrations of GSK-J4,
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Figure 4.2 Continued
measured using CellTiter-Glo. Conditions were measured in quadruplicate. Error bars are
+SEM. (B) Crystal violet staining after 5-7 day treatment with no treatment (no rx) or 2
µM GSK-J4. (C) Western blot analysis of the indicated antibodies, histone modifications
represent global levels after 72-hour treatment no treatment (-) or 2 µM GSK-J4. (D)
FACS analysis of apoptosis after 72-hour treatment with 2 µM GSK-J4 in cell lines
expression an sh-scrambled sequence, or sh-EWS-FLI1 knockdown. The percentage of
induced apoptosis is normalized to the no-treatment controls, error bars are +SEM.
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Figure 4.3 EWS-FLI1 driven genes are reduced following GSK-J4/THZ1 treatment
(A) Western blot analysis of the indicated antibodies of FLI1 target genes after 48-hour
treatment with no-treatment control (no rx), 1 µM GSK-J4, 6-hour treatment with 10 nm
THZ1, or 48-hour 1 µM GSK-J4/6-hour 10 nm THZ1. (B) RNA expression of the
indicated genes following 48-hour treatment with no-treatment control (no rx), 1 µM GSKJ4, 6-hour treatment with 10 nm THZ1, or 48-hour 1 µM GSK-J4/6-hour 10 nm THZ1.
Error bars are +SEM.
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Figure. 4.4 Histone demethylase inhibition slows tumor growth
(A) Patient-derived xenografts treated daily for the indicated timepoint with vehicle
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Figure 4.4 Continued
(DMSO) or GSK-J4 (50mg/kg). Asterisks indicated a significant separation between
treatment cohorts using the Student t test (P < 0.05). Error bars are +SEM (B) Average
measurements of mouse weight (grams) per PDX over the course of each in vivo PDX
from figure 4.4A. Error bars are +SEM.

80

Figure 4.5 GSK-J4 and THZ1 synergistically inhibit EWFT cells and ex vivo PDX models
(A) CellTiter Glo Viability of EWFT cell lines and ex vivo PDX lines, after 48-hour
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Figure 4.5 Continued
treatment with the indicated concentrations of GSK-J4 and THZ1. Data presented as
percent viability and as previously described, depicting percent over the bliss score (91).
Positive scores (red) indicate synergy, negative scores (blue) indicate antagonism. All
concentrations are presented as µM. (B) Western blot analysis of the indicated antibodies,
indicating apoptosis with Cleaved PARP or global changes in histone modifications after
48-hour treatment with no-treatment control (no rx), 1 µM GSK-J4, 6-hour treatment with
10 nm THZ1, or 48-hour 1 µM GSK-J4/6-hour 10 nm THZ1.
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Figure 4.6 The combination of GSK-J4 and THZ1 inhibits EWFT driven gene activation
and reduces tumor growth
(A) ChIP on the putative enhancer regions of the indicated genes at their FLI1 binding
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Figure 4.6 Continued
sites. Cells were fixed and collected after 48-hour treatment with no-treatment control (no
rx), 2 µM GSK-J4, 6-hour treatment with 10 nm THZ1, or 48-hour 2 µM GSK-J4/6-hour
10 nm THZ1 and run using the RT-qPCR conditions described in the materials and
methods section. H3K27ac was calculated as a percentage of input, and statistics was
performed using the Student’s t test. Error bars are +SEM. (B) (left) Patient-derived
xenograft SA10233 treated daily for the indicated timepoint with vehicle (DMSO), GSKJ4 (50mg/kg), THZ1 (10mg/kg), or the combination of GSK-J4 (50mg/kg) + THZ1
(10mg/kg). Asterisks indicated a significant separation between treatment cohorts using
the Student t test (P < 0.05). Error bars are +SEM (145) Average measurements of mouse
weight (grams) over the course of the in vivo experiment from figure 4.6A (left). (C) Fold
change in tumor volume. Please note the data is from figure 4.6A (left) comparing day 1 to
day 32.

84

Figure 4.7 Conceptualized mechanism of co-targeting EWS-FLI1
Cartoon representation of the mechanistic role GSK-J4 plays to inhibit H3K27ac at EWSFLI1 driven transcripts, while cooperatively being downregulated by THZ1 mediated
inhibition of RNAPII activation. (TOP) GSK-J4 reduces EWS-FLI1 driven H3K27ac at
the enhancer regions of EWS-FLI1 bound target genes, resulting in decreased gene
activation. (MIDDLE) THZ1 inhibits CDK7 activity, which results in a loss of RNAPII
phosphorylation at serine 5 and the reduction of oncogenic transcripts. (BOTTOM) THZ1
cooperatively blocks EWS-FLI1 driven transcripts, sensitizing EWFT cells to GSK-J4 and
inhibiting oncogenesis.
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Chapter 5 – General Discussion

Although the occurrence of EWFT is less common than other forms of cancer, this
statistic belies its highly aggressive and deadly nature. Despite recent advances that have
increased EFS of patients with localized disease, the rate of death in patients who relapse
or present with metastasis remains unacceptably high (20, 176). EWFT is unique in that it
has one of the lowest somatic mutation rates among all cancer types which places the
burden of oncogenesis mainly on the FET/ETS fusions which are hallmarks of the disease.
Specifically the t(11;22)(q24;q12) chromosomal translocation which results in the
formation of the EWS-FLI1 oncoprotein is found in 85% of EWFT cases (31). Due to
EWFT’s reliance on FET/ETS translocations, this has been the greatest subject of study for
disease therapy, however this aberrant transcription factor also presents an improbable
drug target. Within the EWFT family there are only a small number of inactivating
mutations in tumor suppressors such as p53 or RB, and other inactivating mutations only
occur in a small subset of the disease such as STAG2 (82). This further suggests that the
main effector of oncogenesis is mediated by the transcriptional and epigenetic changes that
occur as a result of FET/ETS fusions. The future of EWFT treatment rests in our
understanding and exploitation of the transcriptional machinery directed by fusions such as
EWS-FLI1, and how they incur epigenetic dysregulation. There has been extensive
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research describing the vast transcription profile of EWS-FLI1 and its many gene targets
that are dysregulated, however the function and role they play in promoting EWFT
tumorigenesis remains unknown (73, 76, 133).
In cancers such as EWFT where no viable targeted therapies are clinically available
we have to rely on the use of multiple cytotoxic chemotherapeutic agents as the standard of
care such as VDC-IE in EWFT (32-34). Despite our best efforts to develop and utilize
targeted therapies, drug resistance continues to be a challenge. A perfect example of this is
EWFT’s reliance on PARP to assist in the repair of DNA damage due to defects in HR
proteins such as BRCA1. In normal cells, EWSR1 is able to regulate the formation of Rloops: DNA-RNA hybrids which stall replication forks. However, in EWFT cells the
EWS-FLI1 oncoprotein loses this function, leading to a higher incidence of R-loop
formation, which have the ability to sequester and inactivate BRCA1, sensitizing the cells
to cytotoxic and DNA damaging agents such as olaparib (56). However patients failed to
respond to single agent PARPi therapy due to an underappreciated resistance to PARP
inhibition as a result of chemotherapy . The work presented herein represents the
development of combination targeted therapies through the inhibition of EWS-FLI1
machinery and downstream targets.
However, the efficacy of the discussed targeted therapies should be assessed in
additional FET/ETS translocations which cause EWFT. EWSR1 and FUS proteins
(representing 100% of the known FET/ETS fusions which cause EWFT) are involved in
resolving R-loop formation to prevent stalled replication machinery and subsequent DNA
damage, and this function is lost upon FET/ETS fusions (56, 177). This would suggest

87
that the reduced BRCA1 activity found in the EWS-FLI1 fusion is likely to be found in the
entirety of EWFT, as well as their sensitivity to PARP inhibition (94). In addition,
members of the ETS family of transcription factors all bind GGAA motifs, suggesting they
share similar gene targets, and when translocated to a FET protein would result in similar
profiles of gene dysregulation as demonstrated between EWS-FLI1 and EWS-ERG. This
would suggest that the targeted therapies we previously discussed would have efficacy in
non-EWS-FLI1 translocated EWFT due to analogous genomic and epigenetic
dysregulation and susceptibilities (27, 43, 55, 57). This warrants future investigation into
the efficacy of these therapies in the remaining translocations found in EWFT.
We focus on exploiting EWFT reliance on many of the FLI1 target genes and the
use of combination therapies to prevent acquired resistance, leading to the effective
inhibition of EWFT. To this end Chapter 3 reports on a drug combination capable of
overcoming acquired chemotherapy resistance mediated by EWS-FLI1 gene dysregulation.
We report the lack of efficacy towards the PARP inhibitor olaparib was likely mediated by
an upregulation of the anti-apoptotic protein BCL-2, as seen in our pre/post chemotherapy
paired EWFT cell lines CHLA9 and CHLA10. We were able to demonstrate that our
CHLA10 EWFT derived cell line displayed increased BCL-2 expression as a means of
avoiding apoptosis and developing chemotherapy resistance, rendering it insensitive to
PARP inhibitor driven toxicity. Although we did not investigate whether FLI1 binds the
BCL2 enhancer or promoter regions to directly upregulate its expression, we did find a
correlation between expressing the EWS-FLI1 translocation in naïve HEK293T cells and
an increase in BCL-2 levels. We were able to demonstrate that the pro-survival proteins
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BCL-2 and BCL-XL were both capable of resisting olaparib mediated cell death. Given the
transcriptome reprogramming that EWS-FLI1 is capable of, the reliance on the antiapoptotic proteins BCL-2 and BCL-XL mediated by EWS-FLI1 is likely a common method
of acquired chemotherapy resistance in EWFT. To date, the majority of EWFT therapies
have focused on DNA-damaging agents in combination with PARP inhibitors to enhance
their effect (97, 98, 102, 132). Our use of a duel BCL-2/BCL-XL inhibitor to sensitize
EWFT cells to PARP inhibition represents a novel strategy which differs greatly from
those currently being investigated.
Chapter 4 represents a continued investigation of plausible EWS-FLI1 targeted
therapies, with a focus on epigenetically blocking the EWFT transcription machinery.
These studies originated from a HTS drug screen which revealed EWFT were among the
most sensitive cancer type to the histone demethylase inhibitor GSK-J4. We observed
similar levels of sensitivity upon chemical interrogation of an EWFT panel of cell lines
with GSK-J4, and strong efficacy in several PDX models. This sensitivity was determined
to result from the shutting down of global gene activation induced by the EWS-FLI1
translocation and was achieved by preventing H3K27 acetylation through an increase in
H3K27 methylation. We verified this mechanism using targeted ChIP and quantified
H3K27ac levels at FLI1 bound enhancers of several well-known EWS-FLI1 upregulated
genes. Among these genes are: NKX2.2, which is required for oncogenic transformation
and used as a biomarker for EWFT; NPY1R which produces a G Protein coupled receptor
whose function is currently not entirely understood but is often used as a predictor of
EWFT metastasis; and lastly EZH2 which has methyltransferase activity and is responsible
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for altering the active state of chromatin resulting in gene silencing (24, 26, 81). Although
the specific roles that most EWS-FLI1 target genes play in oncogenesis has yet to be
identified, we feel these genes are representative of the epigenetic dysregulation caused by
EWS-FLI1 and serve as a basis for the mechanism of GSK-J4 sensitivity. This work
represents a novel approach, demonstrating GSK-J4 is capable of indirect specificity to the
EWS-FLI1 epigenome with powerful anti-tumor activity.
To avoid possible acquired resistance to GSK-J4 as a monotherapy and enhance its
anti-tumor potential, we utilized current literature citing CDK inhibitors as a promising
new therapeutic opportunity in EWFT (165). By employing a CDK7 inhibitor responsible
for the phosphorylation of RNAPII during initiation, we sought to co-target EWS-FLI1
mediated gene transcription. Our findings demonstrate robust anti-tumor activity against
EWFT both in vitro and in PDX mouse models. Further investigation into CDK7 and
CDK9/12 inhibitors available in clinic is warranted to identify additional small molecule
inhibitors that synergize with GSK-J4 or the next generation of histone demethylase
inhibitors.
Both THZ1 and GSK-J4 vary significantly in the pharmacodynamic rate at which
they act, THZ1 activity peaks at 4-6 hours, while GSK-J4 requires several days to affect
global H3K27me3 levels. Therefore, changes in dose scheduling may be required to exert
the greatest synergistic response. Another potential pitfall to this combination is the effect
these drugs have on global gene expression levels, which manifested in the form of toxicity
in our mouse models. Several of the mice enrolled in the combination cohort of THZ1 and
GSK-J4 lost substantial weight and displayed signs of distress and discomfort which was
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followed by mortality in some instances. Upon autopsy it was revealed that these fatalities
occurred in mice with excessive Constipation or Obstipation. These side effects could be
mitigated pharmaceutically or by altering/lowering the dosing regimen and may have been
a result of the DMSO used as a solvent in both THZ1 and GSK-J4. Despite the side
effects, both drugs demonstrated the ability to control and reduce tumor growth in vivo
supporting the efficacy of our two step approach to block EWS-FLI1 gene transcription.
Previous studies to epigenetically target EWS-FLI1 have focused on HDAC
inhibitors, in order to maintain the activity of tumor suppressors or promote differentiation
(147, 173, 178). Our novel approach is the first of its kind to demonstrate the epigenetic
targeting of EWS-FLI1 through the inhibition of histone methyltransferases. When paired
with highly synergistic CDK7 inhibitors, this represents a new and exciting area of future
research.
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